

COVID-19 Correlates of Risk Analysis Report
MockCOVE Study

USG COVID-19 Response Biostatistics Team

September 23, 2021

Contents

1 Disclaimers	21
2 Summary Tables	23
2.1 Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort	23
2.2 Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort	25
2.3 Sample Sizes of Random Subcohort Strata Plus All Other Cases Outside the Random Subcohort	26
2.4 Availability of immunogenicity data by case status	27
2.5 Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients)	28
2.6 Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients)	30
2.7 Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients)	32
3 Graphical Descriptions of Antibody Marker Data	35
3.1 Boxplots	36
3.2 Weighted RCDF plots	40
3.3 Weighted RCDF plots of threshold correlate concentration for vaccine efficacy	44
3.4 Spaghetti plots	52
3.5 Violin and line plots	53
3.6 Scatter plots	281
4 Graphical Descriptions of Time to Event Data	313
5 Day D29 Univariate CoR: Cox Models of Risk	315
5.1 Hazard ratios	315
5.2 Marginalized risk and controlled vaccine efficacy plots	320
5.3 Misc	336

6 Day D57 Univariate CoR: Cox Models of Risk	339
6.1 Hazard ratios	339
6.2 Marginalized risk and controlled vaccine efficacy plots	344
6.3 Misc	360
7 Univariate CoR: Nonparametric Threshold Modeling ($>=s$)	363
7.1 Plots and Tables with estimates and pointwise confidence interval for Day 57	364
7.2 Plots and Tables with estimates and pointwise confidence intervals for Day 29	365
7.3 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)	366
7.4 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)	367
7.5 Plots and Tables with estimates and simultaneous confidence bands for Day 57	368
7.6 Plots and Tables with estimates and simultaneous confidence bands for Day 29	369
7.7 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)	370
7.8 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)	371
8 Univariate CoR: Nonparametric Threshold Modeling ($<=s$)	373
8.1 Plots and Tables with estimates and pointwise confidence interval for Day 57	373
8.2 Plots and Tables with estimates and pointwise confidence intervals for Day 29	374
8.3 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)	375
8.4 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)	376
8.5 Plots and Tables with estimates and simultaneous confidence bands for Day 57	377
8.6 Plots and Tables with estimates and simultaneous confidence bands for Day 29	378
8.7 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)	379
8.8 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)	380
9 Day D29 Univariate CoR: Nonlinear modeling	381
10 Day D57 Univariate CoR: Nonlinear modeling	383
11 Appendix	385

List of Tables

2.1	Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort	23
2.2	Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort	25
2.3	Table 3. Sample Sizes of Random Subcohort Strata Plus All Other Cases Outside the Random Subcohort	26
2.4	Table 4. Availability of immunogenicity data by case status	27
2.5	Table 5. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients)	28
2.6	Table 6. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients)	30
2.7	Table 7. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients)	32
5.1	Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*	315
5.2	Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*	316
5.3	Analysis of Day 29 markers (upper vs. lower tertile) as a CoR and a controlled risk CoP.	320
5.4	Marginalized cumulative risk by Day 192 as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	327
5.5	Controlled VE as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).Overall cumulative incidence from 7 to 192 days post Day 29 was 0.006 in vaccine recipients compared to 0.102 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.8 to 95.3%).	330
5.6	Controlled VE with sensitivity analysis as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	333
5.7	Deciles of Day 29 cID50 titer for the immunogenicity subcohort in the vaccine arm.	337
5.8	Summary statistics for the number of days from dose 1 to Day 29 visit. (a) The whole immunogenicity subcohort, (b) non-cases in the immunogenicity subcohort, (c) intercurrent cases, (d) primary cases, i.e. cases from the Day 57 correlates analysis population.	337
6.1	Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*	339

6.2	Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*	340
6.3	Analysis of Day 57 markers (upper vs. lower tertile) as a CoR and a controlled risk CoP. . .	344
6.4	Marginalized cumulative risk by Day 164 as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	351
6.5	Controlled VE as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).Overall cumulative incidence from 7 to 164 days post Day 57 was 0.005 in vaccine recipients compared to 0.090 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.7 to 95.6%).	354
6.6	Controlled VE with sensitivity analysis as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).	357
6.7	Deciles of Day 57 cID50 titer for the immunogenicity subcohort in the vaccine arm.	360
6.8	Summary statistics for the number of days from dose 1 to Day 57 visit. (a) The whole immunogenicity subcohort, (b) non-cases in the immunogenicity subcohort, (c) intercurrent cases, (d) primary cases, i.e. cases from the Day 57 correlates analysis population.	361

List of Figures

3.1	Boxplots of D57 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively.	36
3.2	Boxplots of D57 fold-rise over D1 Ab markers: vaccine arm.	37
3.3	Boxplots of D29 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively.	38
3.4	Boxplots of D29 fold-rise over D1 Ab markers: vaccine arm.	39
3.5	RCDF plots for D57 Ab markers by treatment arm.	40
3.6	RCDF plots for D57 fold-rise over D1 Ab markers by treatment arm.	41
3.7	RCDF plots for D29 Ab markers by treatment arm.	42
3.8	RCDF plots for D29 fold-rise over D1 Ab markers by treatment arm.	43
3.9	Marker RCDF of D57 anti-Spike binding Ab: vaccine arm	44
3.10	Marker RCDF of D57 anti-RBD binding Ab: vaccine arm	45
3.11	Marker RCDF of D57 PsV-nAb ID50: vaccine arm	46
3.12	Marker RCDF of D57 PsV-nAb ID80: vaccine arm	47
3.13	Marker RCDF of D29 anti-Spike binding Ab: vaccine arm	48
3.14	Marker RCDF of D29 anti-RBD binding Ab: vaccine arm	49
3.15	Marker RCDF of D29 PsV-nAb ID50: vaccine arm	50
3.16	Marker RCDF of D29 PsV-nAb ID80: vaccine arm	51
3.17	Spaghetti Plots of Marker Trajectory: vaccine arm	52
3.18	lineplots of Binding Antibody to Spike: baseline negative placebo arm (version 1)	53
3.19	lineplots of Binding Antibody to Spike: baseline negative vaccine arm (version 1)	54
3.20	lineplots of Binding Antibody to RBD: baseline negative placebo arm (version 1)	55
3.21	lineplots of Binding Antibody to RBD: baseline negative vaccine arm (version 1)	56
3.22	lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 1)	57
3.23	lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 1)	58
3.24	lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 1)	59
3.25	lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 1)	60
3.26	violinplots of Binding Antibody to Spike: baseline negative placebo arm (version 1)	61
3.27	violinplots of Binding Antibody to Spike: baseline negative vaccine arm (version 1)	62

3.28 violinplots of Binding Antibody to RBD: baseline negative placebo arm (version 1)	63
3.29 violinplots of Binding Antibody to RBD: baseline negative vaccine arm (version 1)	64
3.30 violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 1) . .	65
3.31 violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 1) . . .	66
3.32 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 1) . .	67
3.33 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 1) . . .	68
3.34 lineplots of Binding Antibody to Spike: baseline negative placebo arm (version 2)	69
3.35 lineplots of Binding Antibody to Spike: baseline negative vaccine arm (version 2)	70
3.36 lineplots of Binding Antibody to RBD: baseline negative placebo arm (version 2)	71
3.37 lineplots of Binding Antibody to RBD: baseline negative vaccine arm (version 2)	72
3.38 lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 2) . . .	73
3.39 lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 2) . . .	74
3.40 lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 2) . . .	75
3.41 lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 2) . . .	76
3.42 violinplots of Binding Antibody to Spike: baseline negative placebo arm (version 2)	77
3.43 violinplots of Binding Antibody to Spike: baseline negative vaccine arm (version 2)	78
3.44 violinplots of Binding Antibody to RBD: baseline negative placebo arm (version 2)	79
3.45 violinplots of Binding Antibody to RBD: baseline negative vaccine arm (version 2)	80
3.46 violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 2) . .	81
3.47 violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 2) . .	82
3.48 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 2) . .	83
3.49 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 2) . .	84
3.50 lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 1) . .	85
3.51 lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 1) . .	86
3.52 lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 1) . .	87
3.53 lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 1) . .	88
3.54 lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 1)	89
3.55 lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 1)	90
3.56 lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 1)	91
3.57 lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 1)	92
3.58 violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 1) .	93
3.59 violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 1) . .	94
3.60 violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 1) . .	95
3.61 violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 1) . .	96
3.62 violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 1)	97

3.63 violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 1)	98
3.64 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 1)	99
3.65 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 1)	100
3.66 lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 2)	101
3.67 lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 2)	102
3.68 lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 2)	103
3.69 lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 2)	104
3.70 lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 2)	105
3.71 lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 2)	106
3.72 lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 2)	107
3.73 lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 2)	108
3.74 violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 2)	109
3.75 violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 2)	110
3.76 violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 2)	111
3.77 violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 2)	112
3.78 violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 2)	113
3.79 violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 2)	114
3.80 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 2)	115
3.81 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 2)	116
3.82 lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 1)	117
3.83 lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 1)	118
3.84 lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 1)	119
3.85 lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 1)	120
3.86 lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 1)	121
3.87 lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 1)	122
3.88 lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 1)	123
3.89 lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 1)	124

3.90 violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 1)	125
3.91 violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 1)	126
3.92 violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 1)	127
3.93 violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 1)	128
3.94 violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 1)	129
3.95 violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 1)	130
3.96 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 1)	131
3.97 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 1)	132
3.98 lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 2)	133
3.99 lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 2)	134
3.100lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 2)	135
3.101lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 2)	136
3.102lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 2)	137
3.103lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 2)	138
3.104lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 2)	139
3.105lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 2)	140
3.106violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 2)	141
3.107violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 2)	142
3.108violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 2)	143
3.109violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 2)	144
3.110violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 2)	145
3.111violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 2)	146

3.112violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 2)	147
3.113violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 2)	148
3.114lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 1)	149
3.115lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 1)	150
3.116lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 1)	151
3.117lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 1)	152
3.118lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 1)	153
3.119lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 1)	154
3.120lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 1)	155
3.121lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 1)	156
3.122violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 1)	157
3.123violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 1)	158
3.124violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 1)	159
3.125violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 1)	160
3.126violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 1)	161
3.127violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 1)	162
3.128violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 1)	163
3.129violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 1)	164
3.130lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 2)	165
3.131lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 2)	166
3.132lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 2)	167
3.133lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 2)	168

3.134lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 2)	169
3.135lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 2)	170
3.136lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 2)	171
3.137lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 2)	172
3.138violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 2)	173
3.139violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 2)	174
3.140violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 2)	175
3.141violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 2)	176
3.142violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 2)	177
3.143violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 2)	178
3.144violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 2)	179
3.145violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 2)	180
3.146lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 1)	181
3.147lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 1)	182
3.148lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 1)	183
3.149lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 1)	184
3.150lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 1)	185
3.151lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 1)	186
3.152lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 1)	187
3.153lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 1)	188
3.154violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 1)	189
3.155violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 1)	190

3.156violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 1)	191
3.157violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 1)	192
3.158violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 1)	193
3.159violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 1)	194
3.160violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 1)	195
3.161violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 1)	196
3.162lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 2)	197
3.163lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 2)	198
3.164lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 2)	199
3.165lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 2)	200
3.166lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 2)	201
3.167lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 2)	202
3.168lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 2)	203
3.169lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 2)	204
3.170violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 2)	205
3.171violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 2)	206
3.172violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 2)	207
3.173violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 2)	208
3.174violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 2)	209
3.175violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 2)	210
3.176violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 2)	211
3.177violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 2)	212

3.178lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 1)	213
3.179lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 1)	214
3.180lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 1)	215
3.181lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 1)	216
3.182lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 1)	217
3.183lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 1)	218
3.184lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 1)	219
3.185lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 1)	220
3.186violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 1)	221
3.187violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 1)	222
3.188violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 1)	223
3.189violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 1)	224
3.190violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 1)	225
3.191violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 1)	226
3.192violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 1)	227
3.193violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 1)	228
3.194lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 2)	229
3.195lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 2)	230
3.196lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 2)	231
3.197lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 2)	232
3.198lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 2)	233
3.199lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 2)	234

3.200lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 2)	235
3.201lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 2)	236
3.202violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 2)	237
3.203violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 2)	238
3.204violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 2)	239
3.205violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 2)	240
3.206violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 2)	241
3.207violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 2)	242
3.208violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 2)	243
3.209violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 2)	244
3.210lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)	245
3.211lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)	246
3.212lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)	247
3.213lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)	248
3.214lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)	249
3.215lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)	250
3.216lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)	251
3.217lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)	252
3.218violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)	253
3.219violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)	254
3.220violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)	255
3.221violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)	256

3.222violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)	257
3.223violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)	258
3.224violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)	259
3.225violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)	260
3.226lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)	261
3.227lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)	262
3.228lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)	263
3.229lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)	264
3.230lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)	265
3.231lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)	266
3.232lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)	267
3.233lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)	268
3.234violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)	269
3.235violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)	270
3.236violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)	271
3.237violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)	272
3.238violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)	273
3.239violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)	274
3.240violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)	275
3.241violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)	276
3.242scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 1 . .	281
3.243scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 29 .	282
3.244scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 57 .	283

3.245scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 1	284
3.246scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 29	285
3.247scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 57	286
3.248scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 1	287
3.249scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 29	288
3.250scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 57	289
3.251scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 1	290
3.252scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 29	291
3.253scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 57	292
3.254scatterplots of Binding Antibody to Spike vs Age: by arm at day 1	293
3.255scatterplots of Binding Antibody to Spike vs Age: by arm at day 29	294
3.256scatterplots of Binding Antibody to Spike vs Age: by arm at day 57	295
3.257scatterplots of Binding Antibody to RBD vs Age: by arm at day 1	296
3.258scatterplots of Binding Antibody to RBD vs Age: by arm at day 29	297
3.259scatterplots of Binding Antibody to RBD vs Age: by arm at day 57	298
3.260scatterplots of Pseudovirus Neutralization ID50 vs Age vs Age: by arm at day 1	299
3.261scatterplots of Pseudovirus Neutralization ID50 vs Age vs Age: by arm at day 29	300
3.262scatterplots of Pseudovirus Neutralization ID50 vs Age: by arm at day 57	301
3.263scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 1	302
3.264scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 29	303
3.265scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 57	304
3.266scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 and day 57	305
3.267scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 and day 57	306
3.268scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 and day 57	307
3.269scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 and day 57	308
3.270scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: by arm at day 29 and day 57	309
3.271scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: by arm at day 29 and day 57	310
3.272scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit vs Days Since the Day 29 Visit: by arm at day 29 and day 57	311
3.273scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: by arm at day 29 and day 57	312

4.1	Distribution of the number of days to COVID endpoints, vaccine arm, baseline negative	313
5.1	Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals.	317
5.2	Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to spike markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	318
5.3	Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	318
5.4	Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	319
5.5	Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	319
5.6	Marginalized cumulative incidence rate curves for trichotomized Day 29 markers among baseline negative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.	321
5.7	Marginalized cumulative risk by Day 192 as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.	322
5.8	Controlled VE with sensitivity analysis as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.	323
5.9	Controlled VE with sensitivity analysis as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.	324
5.10	Marginalized cumulative risk by Day 192 post Day 29 visit as functions of Day 29 markers above a threshold ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required, 10 replicates). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.	325
5.11	Controlled VE as functions of Day 29 markers ($>=s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.	326
5.12	Distribution of the number of days between visits in the per-protocol immunogenicity subcohort, vaccine arm, baseline negative. The median (IQR) number of days between Day 1 and Day 29 was 29 (27-31)	336

6.1 Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals.	341
6.2 Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to spike markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	342
6.3 Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	342
6.4 Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	343
6.5 Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.	343
6.6 Marginalized cumulative incidence rate curves for trichotomized Day 57 markers among baseline negative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.	345
6.7 Marginalized cumulative risk by Day 164 as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.	346
6.8 Controlled VE with sensitivity analysis as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.	347
6.9 Controlled VE with sensitivity analysis as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.	348
6.10 Marginalized cumulative risk by Day 164 post Day 57 visit as functions of Day 57 markers above a threshold ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required, 10 replicates). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.	349
6.11 Controlled VE as functions of Day 57 markers ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.	350
6.12 Distribution of the number of days between visits in the per-protocol immunogenicity subcohort, vaccine arm, baseline negative. The median (IQR) number of days between Day 1 and Day 29 was 29 (27-31). The median (IQR) number of days between Day 29 and Day 57 was 28 (25-31).	360

- 9.1 Marginalized risk as functions of Day 29 markers (==s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: baseline risk score, meeting the protocol randomization stratification criterion for being at heightened risk of COVID (yes or no), community of color or not. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. 382
- 10.1 Marginalized risk as functions of Day 57 markers (==s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: baseline risk score, meeting the protocol randomization stratification criterion for being at heightened risk of COVID (yes or no), community of color or not. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. 384

Chapter 1

Disclaimers

The data presented in the analysis are provided to NIAID in accordance with Clinical Trial Agreement between the parties. The study was funded in part by BARDA under Government Contract No. 75A50120C00034.

Statistical Analysis Plan

The SAP is available at <https://doi.org/10.6084/m9.figshare.13198595>

Reproducibility Notice

This project integrates the virtual environments framework provided by the `renv` package for computational reproducibility. By taking this approach, all results are generated using a consistent versioning of both R and several R packages. This version of the report was built with R version 4.0.4 (2021-02-15), `pandoc` version 2.2, and the following R packages:

package	version	source
bookdown	0.21.7	Github (<code>rstudio/bookdown@0cec2fd</code>)
bslib	0.2.4.9002	Github (<code>rstudio/bslib@c7835c2</code>)
data.table	1.14.0	CRAN (R 4.0.4)
delayed	0.4.0	Github (<code>tlverse/delayed@f415340</code>)
devtools	2.3.2	CRAN (R 4.0.4)
dplyr	1.0.5	CRAN (R 4.0.4)
ggplot2	3.3.3	CRAN (R 4.0.4)
hal9001	0.4.0	Github (<code>tlverse/hal9001@14b1630</code>)
haldensify	0.1.5	Github (<code>nhejazi/haldensify@16350cc</code>)
here	1.0.1	CRAN (R 4.0.4)
kableExtra	1.3.4	CRAN (R 4.0.4)
knitr	1.31	CRAN (R 4.0.4)
latex2exp	0.5.0	CRAN (R 4.0.4)
mvtnorm	1.1-1	CRAN (R 4.0.4)
origami	1.0.3	CRAN (R 4.0.4)
readr	1.4.0	CRAN (R 4.0.4)
rmarkdown	2.7.4	Github (<code>rstudio/rmarkdown@a11240d</code>)
skimr	2.1.3	CRAN (R 4.0.4)
sl3	1.4.3	Github (<code>tlverse/sl3@982f4d6</code>)
stringr	1.4.0	CRAN (R 4.0.4)
SuperLearner	2.0-28	CRAN (R 4.0.4)
svyVGAM	1.0	CRAN (R 4.0.4)
tibble	3.1.1	CRAN (R 4.0.4)

package	version	source
tidyr	1.1.3	CRAN (R 4.0.4)
txshift	0.3.6	Github (nhejazi/txshift@c0f572a)
VGAM	1.1-5	CRAN (R 4.0.4)
xtable	1.8-4	CRAN (R 4.0.4)

To get started with using this project and its `renv` package library, we first recommend briefly reviewing the [renv collaboration guide](#).



Chapter 2

Summary Tables

2.1 Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Characteristics	Vaccine (N = 747)	Placebo (N = 138)	Total (N = 885)
Age			
Age < 65	357 (47.8%)	72 (52.2%)	429 (48.5%)
Age ≥ 65	390 (52.2%)	66 (47.8%)	456 (51.5%)
Mean (Range)	58.5 (18.0, 85.0)	58.3 (18.0, 85.0)	58.5 (18.0, 85.0)
BMI			
Mean ± SD	29.7 ± 6.6	31.4 ± 6.3	30.0 ± 6.6
Risk for Severe Covid-19			
At-risk	381 (51.0%)	71 (51.4%)	452 (51.1%)
Not at-risk	366 (49.0%)	67 (48.6%)	433 (48.9%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	185 (24.8%)	36 (26.1%)	221 (25.0%)
Age < 65 Not at-risk	172 (23.0%)	36 (26.1%)	208 (23.5%)
Age ≥ 65	390 (52.2%)	66 (47.8%)	456 (51.5%)
Sex			
Female	427 (57.2%)	75 (54.3%)	502 (56.7%)
Male	320 (42.8%)	63 (45.7%)	383 (43.3%)
Hispanic or Latino ethnicity			
Hispanic or Latino	99 (13.3%)	20 (14.5%)	119 (13.4%)
Not Hispanic or Latino	623 (83.4%)	113 (81.9%)	736 (83.2%)
Not reported and unknown	25 (3.3%)	5 (3.6%)	30 (3.4%)
Race			
White	397 (53.1%)	74 (53.6%)	471 (53.2%)
Black or African American	184 (24.6%)	40 (29.0%)	224 (25.3%)
Asian	56 (7.5%)	10 (7.2%)	66 (7.5%)
American Indian or Alaska Native	16 (2.1%)	2 (1.4%)	18 (2.0%)
Native Hawaiian or Other Pacific Islander	17 (2.3%)	2 (1.4%)	19 (2.1%)

(continued)

Characteristics	Vaccine (N = 747)	Placebo (N = 138)	Total (N = 885)
Multiracial	57 (7.6%)	8 (5.8%)	65 (7.3%)
Other	16 (2.1%)	1 (0.7%)	17 (1.9%)
Not reported and unknown	4 (0.5%)	1 (0.7%)	5 (0.6%)
White Non-Hispanic	370 (49.5%)	63 (45.7%)	433 (48.9%)
Communities of Color	377 (50.5%)	75 (54.3%)	452 (51.1%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

MOCH

2.2 Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Characteristics	Vaccine (N = 234)	Placebo (N = 241)	Total (N = 475)
Age			
Age < 65	114 (48.7%)	120 (49.8%)	234 (49.3%)
Age ≥ 65	120 (51.3%)	121 (50.2%)	241 (50.7%)
Mean (Range)	58.3 (18.0, 85.0)	56.3 (18.0, 85.0)	57.3 (18.0, 85.0)
BMI			
Mean ± SD	29.7 ± 7.5	30.0 ± 6.6	29.9 ± 7.0
Risk for Severe Covid-19			
At-risk	111 (47.4%)	117 (48.5%)	228 (48.0%)
Not at-risk	123 (52.6%)	124 (51.5%)	247 (52.0%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	56 (23.9%)	59 (24.5%)	115 (24.2%)
Age < 65 Not at-risk	58 (24.8%)	61 (25.3%)	119 (25.1%)
Age ≥ 65	120 (51.3%)	121 (50.2%)	241 (50.7%)
Sex			
Female	139 (59.4%)	133 (55.2%)	272 (57.3%)
Male	95 (40.6%)	108 (44.8%)	203 (42.7%)
Hispanic or Latino ethnicity			
Hispanic or Latino	31 (13.2%)	34 (14.1%)	65 (13.7%)
Not Hispanic or Latino	194 (82.9%)	201 (83.4%)	395 (83.2%)
Not reported and unknown	9 (3.8%)	6 (2.5%)	15 (3.2%)
Race			
White	126 (53.8%)	129 (53.5%)	255 (53.7%)
Black or African American	58 (24.8%)	45 (18.7%)	103 (21.7%)
Asian	19 (8.1%)	27 (11.2%)	46 (9.7%)
American Indian or Alaska Native	10 (4.3%)	7 (2.9%)	17 (3.6%)
Native Hawaiian or Other Pacific Islander	4 (1.7%)	2 (0.8%)	6 (1.3%)
Multiracial	10 (4.3%)	16 (6.6%)	26 (5.5%)
Other	7 (3.0%)	13 (5.4%)	20 (4.2%)
Not reported and unknown		2 (0.8%)	2 (0.4%)
White Non-Hispanic	118 (50.4%)	121 (50.2%)	239 (50.3%)
Communities of Color	116 (49.6%)	120 (49.8%)	236 (49.7%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

2.3 Sample Sizes of Random Subcohort Strata Plus All Other Cases Outside the Random Subcohort

Table 3. Sample Sizes of Random Subcohort Strata Plus All Other Cases Outside the Random Subcohort

Sample Sizes of Random Subcohort Strata Plus All Other Cases Outside the Random Subcohort Sample Sizes (N=1360 Participants) (Moderna Trial)																		
	Baseline SARS-CoV-2 Negative									Baseline SARS-CoV-2 Positive								
	1	2	3	4	5	6	7	8	9	1	2	3	4	5	6	7	8	9
Vaccine																		
Day 29 Cases	8	2	3	18	7	12	6	0	3	0	0	2	0	0	0	0	1	0
Day 57 Cases	8	2	1	18	7	9	4	0	3	0	0	2	0	0	0	0	1	0
Non-Cases	153	78	67	235	106	105	69	35	39	48	24	23	72	32	35	26	12	11
Placebo																		
Day 29 Cases	141	48	87	329	109	243	77	31	55	0	0	1	1	1	1	1	0	0
Day 57 Cases	132	37	61	306	93	198	72	27	42	0	0	1	1	1	1	1	0	0
Non-Cases	21	16	16	34	16	18	9	2	3	43	19	22	77	39	38	32	16	9

Demographic covariate strata:

1. Age ≥ 65 , Minority
2. Age < 65 , At risk, Minority
3. Age < 65 , Not at risk, Minority
4. Age ≥ 65 , Non-Minority
5. Age < 65 , At risk, Non-Minority
6. Age < 65 , Not at risk, Non-Minority
7. Age ≥ 65 , Unknown
8. Age < 65 , At risk, Unknown
9. Age < 65 , Not at risk, Unknown

Minority includes Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Native Hawaiians, and other Pacific Islanders.

Non-Minority includes all other races with observed race (Asian, Multiracial, White, Other) and observed ethnicity Not Hispanic or Latino. Participants not classifiable as Minority or Non-Minority because of unknown, unreported or missing were not included.

Observed = Numbers of participants sampled into the subcohort within baseline covariate strata.

Estimated = Estimated numbers of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.

2.4 Availability of immunogenicity data by case status

Table 4. Availability of immunogenicity data by case status

Case	---	--+	-+-	-++	+--	+--	++-	+++
Vaccine								
Day 29 Cases	1	0	0	0	0	0	0	59
Day 57 Cases	0	0	0	0	0	0	0	52
Intercurrent Cases	1	0	0	0	0	0	0	7
Placebo								
Day 29 Cases	49	0	0	0	0	0	0	1120
Day 57 Cases	42	0	0	0	0	0	0	968
Intercurrent Cases	6	0	0	0	0	0	0	146

The + (available) and - (unavailable) in the column labels refer to the availability of the baseline, D29 and D57 markers, respectively.

2.5 Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients)

Table 5. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients)


Visit	Marker	Baseline SARS-CoV-2 Negative Vaccine Recipients						Comparison	
		Cases*		Non-Cases/Control				Resp Rate Difference	GMTR/GMCR
	N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC			
Day 29	Pseudovirus-nAb cID80	59	35.6/60 = 59.3% (46.2%, 71.3%)	21.18 (17.33, 25.87)	744	6530.6/11070 = 59.0% (54.4%, 63.4%)	25.97 (23.98, 28.13)	0 (-0.14, 0.13)	0.82 (0.66, 1.01)
Day 29	Pseudovirus-nAb cID50	59	53.9/60 = 89.8% (78.9%, 95.4%)	16.19 (12.51, 20.95)	744	9932/11070 = 89.7% (86.2%, 92.4%)	17.35 (15.85, 18.99)	0 (-0.11, 0.07)	0.93 (0.71, 1.23)
Day 29	Anti RBD IgG (BAU/ml)	59	60/60 = 100.0% (100.0%, 100.0%)	456.66 (292.67, 712.53)	744	10896.8/11070 = 98.4% (96.6%, 99.3%)	473.53 (412.98, 542.96)	0.02 (0.01, 0.03)	0.96 (0.61, 1.54)
Day 29	Anti Spike IgG (BAU/ml)	59	60/60 = 100.0% (100.0%, 100.0%)	236.57 (169.47, 330.25)	744	10981.5/11070 = 99.2% (97.7%, 99.7%)	266.03 (238.38, 296.89)	0.01 (0, 0.02)	0.89 (0.63, 1.26)
Day 29	Anti N IgG (BAU/ml)	59	35.6/60 = 59.3% (46.2%, 71.3%)	39.18 (24.94, 61.55)	744	6848.9/11070 = 61.9% (57.3%, 66.2%)	36.77 (31.08, 43.49)	-0.03 (-0.16, 0.1)	1.07 (0.66, 1.73)
Day 57	Pseudovirus-nAb cID80	52	52/52 = 100.0% (100.0%, 100.0%)	408.70 (310.06, 538.71)	744	11065/11065 = 100.0% (100.0%, 100.0%)	564.67 (511.70, 623.12)	0 (0, 0)	0.72 (0.54, 0.97)
Day 57	Pseudovirus-nAb cID50	52	52/52 = 100.0% (100.0%, 100.0%)	320.14 (230.41, 444.83)	744	11065/11065 = 100.0% (100.0%, 100.0%)	427.25 (383.62, 475.84)	0 (0, 0)	0.75 (0.53, 1.06)
Day 57	Anti RBD IgG (BAU/ml)	52	52/52 = 100.0% (100.0%, 100.0%)	3325.76 (2232.06, 4955.38)	744	11045.2/11065 = 99.8% (98.7%, 100.0%)	3599.25 (3171.86, 4084.22)	0 (0, 0.01)	0.92 (0.61, 1.40)
Day 57	Anti Spike IgG (BAU/ml)	52	52/52 = 100.0% (100.0%, 100.0%)	1847.33 (1337.98, 2550.57)	744	11065/11065 = 100.0% (100.0%, 100.0%)	2668.40 (2364.64, 3011.17)	0 (0, 0)	0.69 (0.49, 0.98)

Day	Anti N IgG (BAU/ml)	52	$37/52 = 71.2\%$ (57.2%, 82.0%)	71.78 (43.87, 117.44)	744	$8998.4/11065 = 81.3\%$ (77.3%, 84.8%)	110.30 (94.07, 129.33)	-0.1 (-0.25, 0.01)	0.65 (0.39, 1.09)
-----	---------------------	----	------------------------------------	--------------------------	-----	---	---------------------------	-----------------------	----------------------

Cases for Day 29 markers are baseline negative per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 markers are baseline negative per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit. Non-cases/Controls are baseline negative per-protocol vaccine recipients sampled into the random subcohort with no COVID-19 endpoint diagnosis by the time of data-cut.

N is the number of cases sampled into the subcohort within baseline covariate strata.

The denominator in Resp Rate is the number of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.



2.6 Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients)

Table 6. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients)


Visit	Marker	Baseline SARS-CoV-2 Positive Vaccine Recipients						Comparison	
		Cases*		Non-Cases/Control		Resp Rate Difference	GMTR/GMCR		
N	Resp rate	N	Resp rate	GMT/GMC					
Day 29	Pseudovirus-nAb cID80	3 (3.3/5 = 66.7% (0.6%, 99.8%)	28.17 (20.25, 39.20)	234 904.7/1218.1 = 74.3% (66.3%, 80.9%)	51.20 (44.64, 58.73)	-0.08 (-0.74, 0.27)	0.55 (0.38, 0.79)		
Day 29	Pseudovirus-nAb cID50	3 (5/5 = 100.0% (100.0%, 100.0%)	37.31 (35.33, 39.40)	234 1159.7/1218.1 = 95.2% (89.2%, 97.9%)	32.70 (28.11, 38.04)	0.05 (0.02, 0.11)	1.14 (0.97, 1.34)		
Day 29	Anti RBD IgG (BAU/ml)	3 (5/5 = 100.0% (100.0%, 100.0%)	622.59 (124.89, 3103.56)	234 1213.5/1218.1 = 99.6% (97.3%, 99.9%)	823.96 (640.00, 1060.79)	0 (0, 0.03)	0.76 (0.15, 3.84)		
Day 29	Anti Spike IgG (BAU/ml)	3 (5/5 = 100.0% (100.0%, 100.0%)	180.93 (156.70, 208.91)	234 1209.6/1218.1 = 99.3% (95.1%, 99.9%)	474.27 (397.60, 565.71)	0.01 (0, 0.05)	0.38 (0.30, 0.48)		
Day 29	Anti N IgG (BAU/ml)	3 (5/5 = 100.0% (100.0%, 100.0%)	220.52 (99.97, 486.42)	234 928.1/1218.1 = 76.2% (68.6%, 82.4%)	70.68 (55.09, 90.70)	0.24 (0.18, 0.31)	3.12 (1.36, 7.15)		
Day 57	Pseudovirus-nAb cID80	3 (5/5 = 100.0% (100.0%, 100.0%)	1156.48 (486.62, 2748.44)	233 1229/1229 = 100.0% (100.0%, 100.0%)	1559.92 (1333.89, 1824.26)	0 (0, 0)	0.74 (0.31, 1.79)		
Day 57	Pseudovirus-nAb cID50	3 (5/5 = 100.0% (100.0%, 100.0%)	493.08 (319.26, 761.53)	233 1229/1229 = 100.0% (100.0%, 100.0%)	1227.59 (1000.73, 1505.88)	0 (0, 0)	0.40 (0.25, 0.65)		
Day 57	Anti RBD IgG (BAU/ml)	3 (5/5 = 100.0% (100.0%, 100.0%)	15558.50 (14386.64, 16825.81)	233 1229/1229 = 100.0% (100.0%, 100.0%)	8619.19 (7266.78, 10223.28)	0 (0, 0)	1.81 (1.50, 2.18)		
Day 57	Anti Spike IgG (BAU/ml)	3 (5/5 = 100.0% (100.0%, 100.0%)	4871.27 (3719.87, 6379.06)	233 1229/1229 = 100.0% (100.0%, 100.0%)	5665.25 (4956.22, 6475.72)	0 (0, 0)	0.86 (0.64, 1.16)		

Day	Anti N IgG (BAU/ml)	3	$5/5 = 100.0\%$ (100.0%, 100.0%)	293.21 (150.76, 570.25)	233	$1182.5/1229 = 96.2\%$ (90.6%, 98.5%)	248.12 (202.53, 303.97)	0.04 (0.01, 0.09)	1.18 (0.59, 2.37)
57									

The SAP does not specify correlates analyses in baseline positive vaccine recipients. This table summarizes descriptively the same information for baseline positive vaccine recipients that was summarized for baseline negative vaccine recipients. Cases for Day 29 markers are baseline positive per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 markers are baseline positive per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit. Non-cases/Controls are baseline positive per-protocol vaccine recipients sampled into the random subcohort with no COVID-19 endpoint diagnosis by the time of data-cut.

N is the number of cases sampled into the subcohort within baseline covariate strata.

The denominator in Resp Rate is the number of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.



2.7 Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients)

Table 7. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients)


Visit	Marker	Baseline SARS-CoV-2 Positive Placebo Recipients						Comparison	
		Cases*		Non-Cases/Control				Resp Rate Difference	GMTR/GMCR
	N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC			
Day 29	Pseudovirus-nAb cID80	5 (10.6%, 95.0%)	3/5 = 60.0% (9.63, 39.79)	238	442.9/1121 = 39.5% (32.4%, 47.1%)	20.38 (17.86, 23.27)	0.2 (-0.29, 0.56)	0.96 (0.47, 1.98)	
Day 29	Pseudovirus-nAb cID50	5 (5.0%, 89.4%)	2/5 = 40.0% (1.50, 13.28)	238	896.5/1121 = 80.0% (72.4%, 85.9%)	11.68 (9.90, 13.77)	-0.4 (-0.75, 0.1)	0.38 (0.13, 1.15)	
Day 29	Anti RBD IgG (BAU/ml)	5 (100.0%, 100.0%)	5/5 = 100.0% (77.45, 3208.22)	238	1060/1121 = 94.6% (88.4%, 97.5%)	306.92 (232.82, 404.62)	0.05 (0.02, 0.12)	1.62 (0.25, 10.67)	
Day 29	Anti Spike IgG (BAU/ml)	5 (100.0%, 100.0%)	5/5 = 100.0% (74.76, 946.84)	238	1085.9/1121 = 96.9% (91.9%, 98.8%)	170.13 (136.41, 212.19)	0.03 (0.01, 0.08)	1.56 (0.43, 5.67)	
Day 29	Anti N IgG (BAU/ml)	5 (10.6%, 95.0%)	3/5 = 60.0% (2.03, 68.41)	238	603/1121 = 53.8% (45.9%, 61.5%)	26.96 (20.32, 35.77)	0.06 (-0.44, 0.42)	0.44 (0.07, 2.60)	
Day 57	Pseudovirus-nAb cID80	5 (100.0%, 100.0%)	5/5 = 100.0% (114.87, 723.51)	238	1119/1119 = 100.0% (100.0%, 100.0%)	462.73 (395.43, 541.48)	0 (0, 0)	0.62 (0.24, 1.58)	
Day 57	Pseudovirus-nAb cID50	5 (100.0%, 100.0%)	5/5 = 100.0% (128.64, 3076.16)	238	1119/1119 = 100.0% (100.0%, 100.0%)	313.97 (258.96, 380.65)	0 (0, 0)	2.00 (0.40, 9.91)	
Day 57	Anti RBD IgG (BAU/ml)	5 (100.0%, 100.0%)	5/5 = 100.0% (253.44, 11462.91)	238	1119/1119 = 100.0% (100.0%, 100.0%)	2656.74 (2066.29, 3415.92)	0 (0, 0)	0.64 (0.09, 4.39)	
Day 57	Anti Spike IgG (BAU/ml)	5 (100.0%, 100.0%)	5/5 = 100.0% (332.52, 8168.38)	238	1119/1119 = 100.0% (100.0%, 100.0%)	1953.05 (1538.23, 2479.73)	0 (0, 0)	0.84 (0.17, 4.26)	

Day	Anti N IgG (BAU/ml)	5	$3/5 = 60.0\%$ (10.6%, 95.0%)	49.66 (3.50, 703.93)	238	$865.3/1119 = 77.3\%$ (69.5%, 83.6%)	94.81 (70.11, 128.23)	-0.17 (-0.67, 0.19)	0.52 (0.04, 7.55)
57									

Cases for Day 29 markers are baseline positive per-protocol placebo recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 markers are baseline positive per-protocol placebo recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit. Non-cases/Controls are baseline positive per-protocol placebo recipients sampled into the random subcohort with no COVID-19 endpoint diagnosis by the time of data-cut.

N is the number of cases sampled into the subcohort within baseline covariate strata.

The denominator in Resp Rate is the number of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.



MOCK

MOCK

Chapter 3

Graphical Descriptions of Antibody Marker Data

3.1 Boxplots




Figure 3.1: Boxplots of D57 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively.




Figure 3.2: Boxplots of D57 fold-rise over D1 Ab markers: vaccine arm.




Figure 3.3: Boxplots of D29 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively.




Figure 3.4: Boxplots of D29 fold-rise over D1 Ab markers: vaccine arm.

3.2 Weighted RCDF plots




Figure 3.5: RCDF plots for D57 Ab markers by treatment arm.




Figure 3.6: RCDF plots for D57 fold-rise over D1 Ab markers by treatment arm.




Figure 3.7: RCDF plots for D29 Ab markers by treatment arm.




Figure 3.8: RCDF plots for D29 fold-rise over D1 Ab markers by treatment arm.

3.3 Weighted RCDF plots of threshold correlate concentration for vaccine efficacy




Figure 3.9: Marker RCDF of D57 anti-Spike binding Ab: vaccine arm

3.3. WEIGHTED RCDF PLOTS OF THRESHOLD CORRELATE CONCENTRATION FOR VACCINE EFFICACY 45




Figure 3.10: Marker RCDF of D57 anti-RBD binding Ab: vaccine arm




Figure 3.11: Marker RCDF of D57 PsV-nAb ID50: vaccine arm

3.3. WEIGHTED RCDF PLOTS OF THRESHOLD CORRELATE CONCENTRATION FOR VACCINE EFFICACY47




Figure 3.12: Marker RCDF of D57 PsV-nAb ID80: vaccine arm




Figure 3.13: Marker RCDF of D29 anti-Spike binding Ab: vaccine arm




Figure 3.14: Marker RCDF of D29 anti-RBD binding Ab: vaccine arm




Figure 3.15: Marker RCDF of D29 PsV-nAb ID50: vaccine arm

3.3. WEIGHTED RCDF PLOTS OF THRESHOLD CORRELATE CONCENTRATION FOR VACCINE EFFICACY51




Figure 3.16: Marker RCDF of D29 PsV-nAb ID80: vaccine arm

3.4 Spaghetti plots




Figure 3.17: Spaghetti Plots of Marker Trajectory: vaccine arm

3.5 Violin and line plots




Figure 3.18: lineplots of Binding Antibody to Spike: baseline negative placebo arm (version 1)




Figure 3.19: lineplots of Binding Antibody to Spike: baseline negative vaccine arm (version 1)




Figure 3.20: lineplots of Binding Antibody to RBD: baseline negative placebo arm (version 1)




Figure 3.21: lineplots of Binding Antibody to RBD: baseline negative vaccine arm (version 1)





Figure 3.22: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 3.23: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 1)




Figure 3.24: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 1)




Figure 3.25: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 1)




Figure 3.26: violinplots of Binding Antibody to Spike: baseline negative placebo arm (version 1)




Figure 3.27: violinplots of Binding Antibody to Spike: baseline negative vaccine arm (version 1)




Figure 3.28: violinplots of Binding Antibody to RBD: baseline negative placebo arm (version 1)




Figure 3.29: violinplots of Binding Antibody to RBD: baseline negative vaccine arm (version 1)




Figure 3.30: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 1)




Figure 3.31: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 1)




Figure 3.32: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 1)




Figure 3.33: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 1)




Figure 3.34: lineplots of Binding Antibody to Spike: baseline negative placebo arm (version 2)





Figure 3.35: lineplots of Binding Antibody to Spike: baseline negative vaccine arm (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.36: lineplots of Binding Antibody to RBD: baseline negative placebo arm (version 2)




Figure 3.37: lineplots of Binding Antibody to RBD: baseline negative vaccine arm (version 2)




Figure 3.38: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 2)




Figure 3.39: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 2)




Figure 3.40: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 2)




Figure 3.41: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 2)




Figure 3.42: violinplots of Binding Antibody to Spike: baseline negative placebo arm (version 2)




Figure 3.43: violinplots of Binding Antibody to Spike: baseline negative vaccine arm (version 2)




Figure 3.44: violinplots of Binding Antibody to RBD: baseline negative placebo arm (version 2)




Figure 3.45: violinplots of Binding Antibody to RBD: baseline negative vaccine arm (version 2)




Figure 3.46: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 2)




Figure 3.47: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 2)




Figure 3.48: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 2)






Figure 3.49: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.50: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.51: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 1)




Figure 3.52: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 1)





Figure 3.53: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.54: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 1)




Figure 3.55: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 1)





Figure 3.56: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.57: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 1)




Figure 3.58: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 1)




Figure 3.59: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 1)




Figure 3.60: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 1)




Figure 3.61: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 1)




Figure 3.62: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 1)




Figure 3.63: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 1)




Figure 3.64: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 1)






Figure 3.65: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.66: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.67: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.68: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 2)




Figure 3.69: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 2)




Figure 3.70: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 2)






Figure 3.71: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.72: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.73: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 2)




Figure 3.74: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 2)




Figure 3.75: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 2)




Figure 3.76: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 2)




Figure 3.77: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 2)




Figure 3.78: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 2)




Figure 3.79: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 2)




Figure 3.80: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 2)






Figure 3.81: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.82: lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.83: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.84: lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 3.85: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.86: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.87: lineplots of Pseudovirus Neutralization ID₅₀: baseline negative vaccine arm by risk condition (version 1)





Figure 3.88: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.89: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 1)




Figure 3.90: violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 1)




Figure 3.91: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 1)




Figure 3.92: violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 1)




Figure 3.93: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 1)




Figure 3.94: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 1)




Figure 3.95: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 1)




Figure 3.96: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 1)






Figure 3.97: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 3.98: lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.99: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.100: lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.101: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.102: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.103: lineplots of Pseudovirus Neutralization ID₅₀: baseline negative vaccine arm by risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.104: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.105: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 2)




Figure 3.106: violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 2)




Figure 3.107: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 2)




Figure 3.108: violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 2)




Figure 3.109: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 2)




Figure 3.110: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 2)




Figure 3.111: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 2)




Figure 3.112: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 2)




Figure 3.113: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 2)




Figure 3.114: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 1)





Figure 3.115: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.116: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 1)






Figure 3.117: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.118: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.119: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.120: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.121: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.122: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.123: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.124: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.125: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.126: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.127: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.128: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 1)






Figure 3.129: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 3.130: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.131: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.132: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 2)






Figure 3.133: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.134: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.135: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.136: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.137: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.138: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.139: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.140: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.141: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.142: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.143: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.144: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 2)






Figure 3.145: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.146: lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 3.147: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 1)






Figure 3.148: lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.149: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.150: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 1)





Figure 3.151: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger

Figure 3.152: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.153: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.154: violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.155: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.156: violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.157: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.158: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.159: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.160: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 1)






Figure 3.161: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.162: lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.163: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 2)






Figure 3.164: lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.165: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.166: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.167: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.168: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.169: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.170: violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.171: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 2)

Binding Antibody to RBD




Figure 3.172: violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.173: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.174: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.175: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.176: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 2)






Figure 3.177: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.178: lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.179: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.180: lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 1)






Figure 3.181: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 1)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.182: lineplots of Pseudovirus Neutralization ID₅₀: baseline negative placebo arm by race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.183: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.184: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.185: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.186: violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.187: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.188: violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.189: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.190: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.191: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.192: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 1)






Figure 3.193: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.194: lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.195: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 2)






Figure 3.196: lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.197: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.198: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.199: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.200: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.201: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.202: violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.203: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.204: violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.205: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.206: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.207: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.208: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 2)






Figure 3.209: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.210: lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.211: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.212: lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)





Figure 3.213: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.214: lineplots of Pseudovirus Neutralization ID₅₀: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)






Figure 3.215: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.216: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.217: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.218: violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.219: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.220: violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.221: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.222: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.223: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.224: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.225: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)





Figure 3.226: lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.227: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.228: lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)






Figure 3.229: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.230: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.231: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.232: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)



All data points for cases are shown. Non-Case data points are shown for all eligible participants or for a random sample of 100 eligible participants, whichever is larger.

Figure 3.233: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.234: violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.235: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.236: violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.237: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.238: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.239: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.240: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.241: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)

MOCK

MOCK

MOCK

MOCK

3.6 Scatter plots




Figure 3.242: scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 1




Figure 3.243: scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 29




Figure 3.244: scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 57




Figure 3.245: scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 1




Figure 3.246: scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 29




Figure 3.247: scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 57




Figure 3.248: scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 1




Figure 3.249: scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 29




Figure 3.250: scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 57




Figure 3.251: scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 1




Figure 3.252: scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 29




Figure 3.253: scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 57




Figure 3.254: scatterplots of Binding Antibody to Spike vs Age: by arm at day 1




Figure 3.255: scatterplots of Binding Antibody to Spike vs Age: by arm at day 29




Figure 3.256: scatterplots of Binding Antibody to Spike vs Age: by arm at day 57




Figure 3.257: scatterplots of Binding Antibody to RBD vs Age: by arm at day 1




Figure 3.258: scatterplots of Binding Antibody to RBD vs Age: by arm at day 29




Figure 3.259: scatterplots of Binding Antibody to RBD vs Age: by arm at day 57




Figure 3.260: scatterplots of Pseudovirus Neutralization ID50 vs Age vs Age: by arm at day 1




Figure 3.261: scatterplots of Pseudovirus Neutralization ID50 vs Age vs Age: by arm at day 29




Figure 3.262: scatterplots of Pseudovirus Neutralization ID50 vs Age: by arm at day 57




Figure 3.263: scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 1




Figure 3.264: scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 29




Figure 3.265: scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 57




Figure 3.266: scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 and day 57




Figure 3.267: scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 and day 57




Figure 3.268: scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 and day 57




Figure 3.269: scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 and day 57




Figure 3.270: scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: by arm at day 29 and day 57




Figure 3.271: scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: by arm at day 29 and day 57




Figure 3.272: scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit vs Days Since the Day 29 Visit: by arm at day 29 and day 57




Figure 3.273: scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: by arm at day 29 and day 57

Chapter 4

Graphical Descriptions of Time to Event Data




Figure 4.1: Distribution of the number of days to COVID endpoints, vaccine arm, baseline negative.

MOCK

Chapter 5

Day D29 Univariate CoR: Cox Models of Risk

The main regression model is the Cox proportional hazards model. All plots are made with Cox models fit unless specified otherwise.

5.1 Hazard ratios

Table 5.1: Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*

MockCOVE Immunologic Marker	No. cases / No. at-risk**	HR per 10-fold incr. Pt. Est.	95% CI	P-value (2-sided)	q-value ***	FWER
Anti Spike IgG (BAU/ml)	60/11,157	0.30	(0.17-0.53)	<0.001	<0.001	<0.001
Anti RBD IgG (BAU/ml)	60/11,157	0.50	(0.30-0.84)	0.010	<0.001	<0.001
Pseudovirus-nAb cID50	60/11,157	0.43	(0.22-0.85)	0.016	<0.001	<0.001
Pseudovirus-nAb cID80	60/11,157	0.35	(0.18-0.68)	0.002	<0.001	<0.001

*Baseline covariates adjusted for: baseline risk score, meeting the protocol randomization stratification criterion for being at heightened risk of COVID (yes or no), community of color or not. Maximum failure event time 192 days.

**No. at-risk = estimated number in the population for analysis: baseline negative per-protocol vaccine recipients not experiencing the COVID endpoint through 6 days post Day 29 visit; no. cases = number of this cohort with an observed COVID endpoint.

***q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers using the Westfall and Young permutation method (10 replicates).

Table 5.2: Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*

MockCOVE Immunologic Marker	Tertile	No. cases / No. at-risk**	Attack rate	Pt. Est.	Haz. Ratio 95% CI	P-value (2-sided)	Overall P- value***	Overall q- value †	Overall FWER
Anti Spike IgG (BAU/ml)	Lower	20/3,702	0.0054	1	N/A	N/A	0.003	<0.001	<0.001
	Middle	19/3,705	0.0051	0.56	(0.27-1.13)	0.107			
	Upper	20/3,750	0.0053	0.25	(0.11-0.56)	<0.001			
Anti RBD IgG (BAU/ml)	Lower	26/3,722	0.0070	1	N/A	N/A	0.001	<0.001	<0.001
	Middle	13/3,740	0.0035	0.32	(0.15-0.66)	0.002			
	Upper	20/3,695	0.0054	0.28	(0.13-0.60)	<0.001			
Pseudovirus-nAb cID50	Lower	20/3,690	0.0054	1	N/A	N/A	0.050	<0.001	0.013
	Middle	23/3,749	0.0061	0.97	(0.50-1.90)	0.935			
	Upper	16/3,718	0.0043	0.45	(0.21-0.95)	0.037			
Pseudovirus-nAb cID80	Lower	20/3,754	0.0053	1	N/A	N/A	0.026	<0.001	<0.001
	Middle	26/3,719	0.0070	1.16	(0.61-2.19)	0.653			
	Upper	13/3,685	0.0035	0.45	(0.21-0.95)	0.038			
Placebo		1112/11,426	0.0973						

*Baseline covariates adjusted for: baseline risk score, meeting the protocol randomization stratification criterion for being at heightened risk of COVID (yes or no), community of color or not. Maximum failure event time 192 days. Cutpoints: Anti Spike IgG (BAU/ml) [2.14, 2.65], Anti RBD IgG (BAU/ml) [2.37, 2.98], Pseudovirus-nAb cID50 [1.07, 1.45], Pseudovirus-nAb cID80 [1.26, 1.61], all on the log10 scale.

**No. at-risk = estimated number in the population for analysis: baseline negative per-protocol vaccine recipients not experiencing the COVID endpoint through 6 days post Day 29 visit; no. cases = number of this cohort with an observed COVID endpoint.

***Generalized Wald-test p-value of the null hypothesis that the hazard rate is constant across the Lower, Middle, and Upper tertile groups.

† q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers using the Westfall and Young permutation method (10 replicates).




Figure 5.1: Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals.

Binding Antibody to Spike: Day 29




Figure 5.2: Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to spike markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

Binding Antibody to RBD: Day 29




Figure 5.3: Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

PsV Neutralization 50% Titer: Day 29




Figure 5.4: Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

PsV Neutralization 80% Titer: Day 29




Figure 5.5: Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

5.2 Marginalized risk and controlled vaccine efficacy plots

MOCK

Table 5.3: Analysis of Day 29 markers (upper vs. lower tertile) as a CoR and a controlled risk CoP.

	marginalized risk		controlled risk		$e(0,1)^2$	
	ratio $RR_M(0, 1)$	Point Est. 95% CI	ratio $RR_C(0, 1)^1$	Point Est. 95% CI	Point Est. 95% CI UL	
Anti Spike IgG (BAU/ml)	0.25	0.13–0.69	0.34	0.17–0.92	7.4	2.3
Anti RBD IgG (BAU/ml)	0.29	0.16–0.73	0.38	0.21–0.97	6.4	2.1
Pseudovirus-nAb cID50	0.45	0.21–0.80	0.60	0.29–1.07	3.9	1.8
Pseudovirus-nAb cID80	0.45	0.24–0.81	0.60	0.32–1.08	3.9	1.8

¹Conservative (upper bound) estimate assuming unmeasured confounding at level $RR_{UD}(0, 1) = RR_{EU}(0, 1) = 2$ and thus $B(0, 1) = 4/3$.

²E-values are computed for upper tertile ($s = 1$) vs. lower tertile ($s = 0$) biomarker subgroups after controlling for baseline risk score, meeting the protocol randomization stratification criterion for being at heightened risk of COVID (yes or no), community of color or not; UL = upper limit.




Figure 5.6: Marginalized cumulative incidence rate curves for trichotomized Day 29 markers among baseline negative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.




Figure 5.7: Marginalized cumulative risk by Day 192 as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.




Figure 5.8: Controlled VE with sensitivity analysis as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $\text{lod} = 0.3$ for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.




Figure 5.9: Controlled VE with sensitivity analysis as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $\text{lod} = 0.3$ for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.




Figure 5.10: Marginalized cumulative risk by Day 192 post Day 29 visit as functions of Day 29 markers above a threshold ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required, 10 replicates). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 0.3$ for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.




Figure 5.11: Controlled VE as functions of Day 29 markers ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 0.3$ for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.

Table 5.4: Marginalized cumulative risk by Day 192 as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

	Anti Spike IgG (BAU/ml)	Anti RBD IgG (BAU/ml)	Pseudovirus-nAb cID50	Pseudovirus-nAb cID80			
s	Estimate	s	Estimate	s	Estimate	s	Estimate
4.1	.0549 (.0136,.1427)	6.8	.0215 (.0052,.0503)	1.2	.0153 (.0070,.0395)	7.5	.0096 (.0067,.0160)
4	.0528 (.0134,.1364)	7	.0210 (.0052,.0486)	1	.0149 (.0069,.0378)	8	.0096 (.0067,.0160)
5	.0509 (.0132,.1303)	8	.0205 (.0052,.0470)	1	.0146 (.0069,.0363)	8	.0096 (.0067,.0160)
5	.0490 (.0129,.1243)	9	.0201 (.0052,.0454)	1	.0142 (.0069,.0348)	8	.0094 (.0066,.0155)
6	.0471 (.0127,.1186)	9	.0196 (.0052,.0439)	2	.0139 (.0068,.0333)	8	.0092 (.0066,.0150)
6	.0454 (.0125,.1131)	10	.0192 (.0052,.0424)	2	.0136 (.0068,.0319)	9	.0090 (.0065,.0145)
7	.0437 (.0123,.1078)	11	.0187 (.0052,.0409)	2	.0133 (.0067,.0306)	9	.0089 (.0065,.0140)
7	.0420 (.0121,.1027)	12	.0183 (.0052,.0395)	2	.0129 (.0067,.0293)	9	.0087 (.0064,.0136)
8	.0404 (.0119,.0977)	13	.0179 (.0051,.0382)	2	.0126 (.0066,.0281)	10	.0085 (.0064,.0131)
8	.0389 (.0117,.0930)	14	.0175 (.0051,.0369)	2	.0123 (.0066,.0269)	10	.0084 (.0063,.0127)
9	.0374 (.0115,.0884)	15	.0171 (.0051,.0356)	2	.0121 (.0065,.0257)	11	.0082 (.0063,.0123)
10	.0360 (.0113,.0840)	16	.0167 (.0051,.0344)	2	.0118 (.0065,.0247)	11	.0081 (.0062,.0119)
11	.0346 (.0112,.0798)	18	.0163 (.0051,.0332)	3	.0115 (.0064,.0236)	12	.0079 (.0062,.0115)
11	.0333 (.0110,.0758)	19	.0159 (.0051,.0321)	3	.0112 (.0064,.0226)	12	.0078 (.0061,.0112)
12	.0320 (.0108,.0720)	20	.0156 (.0051,.0310)	3	.0110 (.0064,.0216)	13	.0076 (.0060,.0108)
13	.0308 (.0106,.0683)	22	.0152 (.0051,.0299)	3	.0107 (.0063,.0207)	13	.0075 (.0060,.0105)
15	.0296 (.0104,.0647)	24	.0149 (.0051,.0289)	3	.0105 (.0063,.0198)	14	.0073 (.0059,.0102)
16	.0284 (.0103,.0614)	26	.0145 (.0051,.0279)	4	.0102 (.0062,.0190)	14	.0072 (.0058,.0098)
17	.0273 (.0101,.0582)	28	.0142 (.0051,.0269)	4	.0100 (.0062,.0182)	15	.0070 (.0058,.0095)
18	.0263 (.0099,.0551)	30	.0139 (.0051,.0260)	4	.0097 (.0062,.0174)	15	.0070 (.0057,.0094)
20	.0253 (.0098,.0522)	33	.0135 (.0051,.0251)	4	.0095 (.0061,.0167)	16	.0069 (.0057,.0092)
22	.0243 (.0096,.0494)	36	.0132 (.0051,.0242)	5	.0093 (.0061,.0160)	16	.0068 (.0056,.0089)
23	.0233 (.0095,.0467)	38	.0129 (.0051,.0234)	5	.0091 (.0060,.0153)	17	.0067 (.0056,.0087)
25	.0224 (.0093,.0442)	42	.0126 (.0050,.0225)	5	.0089 (.0060,.0146)	18	.0065 (.0055,.0084)
27	.0215 (.0091,.0418)	45	.0123 (.0050,.0218)	6	.0087 (.0059,.0140)	18	.0064 (.0055,.0081)
30	.0207 (.0090,.0395)	49	.0121 (.0050,.0210)	6	.0085 (.0059,.0136)	19	.0063 (.0054,.0079)
32	.0199 (.0088,.0374)	53	.0118 (.0050,.0203)	6	.0085 (.0059,.0134)	20	.0062 (.0053,.0076)
35	.0191 (.0087,.0353)	57	.0115 (.0050,.0195)	7	.0083 (.0059,.0128)	21	.0060 (.0052,.0074)
37	.0184 (.0086,.0334)	62	.0112 (.0050,.0189)	7	.0081 (.0058,.0123)	22	.0059 (.0051,.0072)
40	.0176 (.0084,.0315)	67	.0110 (.0050,.0182)	7	.0079 (.0058,.0117)	22	.0059 (.0051,.0072)
44	.0169 (.0083,.0298)	72	.0107 (.0050,.0175)	8	.0078 (.0058,.0114)	23	.0058 (.0050,.0069)
47	.0163 (.0081,.0281)	78	.0105 (.0050,.0169)	8	.0077 (.0058,.0112)	24	.0057 (.0049,.0067)
51	.0156 (.0080,.0265)	78	.0105 (.0050,.0169)	9	.0075 (.0057,.0107)	25	.0056 (.0048,.0065)
56	.0150 (.0079,.0251)	84	.0102 (.0050,.0163)	9	.0073 (.0057,.0103)	26	.0055 (.0047,.0063)
60	.0144 (.0077,.0237)	91	.0100 (.0050,.0158)	10	.0072 (.0056,.0098)	27	.0054 (.0046,.0061)
64	.0140 (.0076,.0226)	99	.0098 (.0050,.0152)	10	.0072 (.0056,.0098)	28	.0054 (.0045,.0061)
65	.0138 (.0076,.0223)	107	.0096 (.0050,.0147)	10	.0070 (.0056,.0094)	28	.0053 (.0045,.0059)
70	.0133 (.0075,.0211)	115	.0093 (.0050,.0141)	11	.0068 (.0056,.0090)	30	.0052 (.0044,.0058)
76	.0128 (.0074,.0199)	125	.0091 (.0050,.0136)	12	.0067 (.0055,.0086)	31	.0051 (.0043,.0056)
82	.0123 (.0072,.0188)	125	.0091 (.0050,.0136)	13	.0065 (.0055,.0083)	32	.0050 (.0042,.0055)
84	.0121 (.0072,.0185)	135	.0089 (.0050,.0132)	13	.0064 (.0054,.0079)	34	.0049 (.0041,.0054)
89	.0118 (.0071,.0178)	146	.0087 (.0050,.0127)	14	.0063 (.0054,.0077)	35	.0048 (.0040,.0053)
96	.0113 (.0070,.0168)	158	.0085 (.0050,.0122)	14	.0062 (.0054,.0076)	35	.0048 (.0040,.0053)
104	.0109 (.0069,.0159)	171	.0083 (.0050,.0118)	15	.0061 (.0053,.0074)	37	.0047 (.0039,.0052)
113	.0104 (.0068,.0150)	185	.0081 (.0050,.0114)	16	.0059 (.0051,.0071)	38	.0046 (.0038,.0051)
121	.0101 (.0067,.0143)	188	.0081 (.0050,.0113)	17	.0058 (.0050,.0068)	40	.0045 (.0037,.0050)
122	.0100 (.0067,.0142)	200	.0079 (.0050,.0110)	19	.0056 (.0048,.0065)	42	.0044 (.0036,.0049)
132	.0096 (.0066,.0134)	216	.0077 (.0050,.0106)	19	.0056 (.0048,.0065)	43	.0044 (.0036,.0049)
143	.0092 (.0064,.0126)	234	.0076 (.0050,.0103)	20	.0055 (.0047,.0063)	44	.0044 (.0035,.0049)

155	.0089 (.0063,.0119)	253	.0074 (.0050,.0099)	21	.0054 (.0045,.0061)	45	.0043 (.0034,.0048)
168	.0085 (.0062,.0113)	274	.0072 (.0050,.0096)	23	.0053 (.0043,.0060)	47	.0042 (.0033,.0047)
181	.0082 (.0061,.0106)	296	.0070 (.0050,.0092)	24	.0051 (.0041,.0059)	50	.0041 (.0032,.0046)
196	.0078 (.0060,.0100)	320	.0069 (.0050,.0089)	24	.0051 (.0041,.0059)	52	.0040 (.0032,.0046)
212	.0075 (.0059,.0095)	347	.0067 (.0050,.0086)	26	.0050 (.0040,.0058)	54	.0040 (.0031,.0045)
224	.0073 (.0058,.0091)	375	.0066 (.0050,.0083)	27	.0049 (.0038,.0057)	56	.0039 (.0030,.0045)
230	.0072 (.0058,.0089)	376	.0066 (.0050,.0083)	29	.0048 (.0037,.0057)	59	.0038 (.0029,.0045)
249	.0069 (.0057,.0085)	406	.0064 (.0050,.0080)	30	.0047 (.0036,.0056)	61	.0037 (.0028,.0044)
269	.0067 (.0056,.0080)	439	.0063 (.0050,.0078)	31	.0047 (.0035,.0056)	63	.0037 (.0028,.0044)
291	.0064 (.0055,.0076)	474	.0061 (.0050,.0075)	33	.0046 (.0034,.0055)	64	.0037 (.0028,.0044)
315	.0061 (.0053,.0072)	500	.0060 (.0050,.0073)	36	.0044 (.0032,.0054)	67	.0036 (.0027,.0044)
333	.0060 (.0051,.0069)	513	.0060 (.0050,.0072)	38	.0043 (.0031,.0054)	70	.0035 (.0026,.0043)
341	.0059 (.0050,.0068)	555	.0058 (.0050,.0070)	41	.0042 (.0030,.0053)	73	.0035 (.0025,.0043)
369	.0056 (.0048,.0064)	601	.0057 (.0050,.0067)	43	.0041 (.0029,.0052)	74	.0034 (.0025,.0043)
399	.0054 (.0045,.0061)	603	.0057 (.0050,.0067)	45	.0041 (.0028,.0052)	76	.0034 (.0025,.0043)
432	.0052 (.0043,.0059)	650	.0056 (.0049,.0065)	46	.0040 (.0027,.0052)	79	.0033 (.0024,.0042)
468	.0050 (.0040,.0056)	703	.0054 (.0048,.0063)	49	.0039 (.0026,.0051)	83	.0033 (.0023,.0042)
475	.0050 (.0040,.0056)	760	.0053 (.0046,.0061)	53	.0039 (.0025,.0051)	87	.0032 (.0023,.0041)
500	.0048 (.0038,.0055)	822	.0052 (.0045,.0059)	55	.0038 (.0024,.0050)	90	.0031 (.0022,.0041)
506	.0048 (.0038,.0054)	889	.0051 (.0043,.0058)	56	.0038 (.0024,.0050)	90	.0031 (.0022,.0041)
548	.0046 (.0036,.0053)	912	.0050 (.0043,.0058)	60	.0037 (.0023,.0050)	94	.0031 (.0021,.0041)
593	.0044 (.0034,.0051)	962	.0050 (.0042,.0057)	64	.0036 (.0022,.0049)	98	.0030 (.0021,.0040)
641	.0042 (.0032,.0049)	1000	.0049 (.0041,.0057)	68	.0035 (.0021,.0049)	103	.0030 (.0020,.0040)
693	.0041 (.0030,.0048)	1041	.0048 (.0040,.0056)	71	.0035 (.0020,.0048)	107	.0029 (.0019,.0040)
694	.0041 (.0030,.0048)	1126	.0047 (.0039,.0055)	73	.0034 (.0020,.0048)	112	.0028 (.0019,.0039)
751	.0039 (.0028,.0047)	1218	.0046 (.0038,.0055)	78	.0033 (.0019,.0048)	117	.0028 (.0018,.0039)
813	.0037 (.0027,.0046)	1317	.0045 (.0037,.0054)	83	.0033 (.0018,.0047)	122	.0027 (.0018,.0039)
879	.0036 (.0025,.0045)	1395	.0044 (.0036,.0054)	89	.0032 (.0017,.0047)	127	.0027 (.0017,.0039)
952	.0035 (.0024,.0045)	1425	.0044 (.0035,.0054)	94	.0031 (.0017,.0046)	133	.0026 (.0017,.0038)
1000	.0034 (.0023,.0044)	1541	.0043 (.0034,.0053)	101	.0030 (.0016,.0046)	139	.0026 (.0016,.0038)
1030	.0033 (.0022,.0044)	1667	.0042 (.0033,.0053)	108	.0030 (.0015,.0045)	145	.0025 (.0016,.0038)
1114	.0032 (.0021,.0043)	1804	.0041 (.0032,.0053)	115	.0029 (.0015,.0045)	151	.0025 (.0015,.0037)
1206	.0031 (.0020,.0042)	1951	.0040 (.0031,.0053)	123	.0028 (.0014,.0044)	158	.0024 (.0015,.0037)
1294	.0029 (.0019,.0042)	2111	.0039 (.0030,.0053)	131	.0028 (.0013,.0044)	165	.0024 (.0014,.0037)
1305	.0029 (.0019,.0041)	2283	.0038 (.0029,.0053)	140	.0027 (.0013,.0044)	172	.0023 (.0014,.0036)
1412	.0028 (.0018,.0041)	2470	.0037 (.0028,.0053)	149	.0026 (.0012,.0043)	179	.0023 (.0013,.0036)
1528	.0027 (.0017,.0040)	2671	.0037 (.0027,.0053)	159	.0026 (.0012,.0043)	187	.0023 (.0013,.0036)
1653	.0026 (.0016,.0039)	2890	.0036 (.0026,.0053)	170	.0025 (.0011,.0043)	195	.0022 (.0012,.0035)
1785	.0025 (.0015,.0039)	2891	.0036 (.0026,.0053)	181	.0024 (.0011,.0042)	204	.0022 (.0012,.0035)
1789	.0025 (.0015,.0039)	3126	.0035 (.0025,.0053)	193	.0024 (.0010,.0042)	213	.0021 (.0012,.0035)
1936	.0024 (.0014,.0038)	3381	.0034 (.0024,.0053)	206	.0023 (.0010,.0042)	222	.0021 (.0011,.0035)
2095	.0023 (.0013,.0037)	3658	.0033 (.0024,.0053)	220	.0023 (.0009,.0042)	232	.0021 (.0011,.0034)
2228	.0022 (.0012,.0037)	3957	.0032 (.0023,.0053)	235	.0022 (.0009,.0041)	242	.0020 (.0011,.0034)
2267	.0022 (.0012,.0037)	4073	.0032 (.0022,.0053)	251	.0022 (.0008,.0041)	253	.0020 (.0010,.0034)
2453	.0021 (.0012,.0036)	4280	.0032 (.0022,.0053)	267	.0021 (.0008,.0041)	264	.0019 (.0010,.0033)
2655	.0020 (.0011,.0035)	4630	.0031 (.0021,.0053)	285	.0021 (.0008,.0040)	275	.0019 (.0010,.0033)
2873	.0019 (.0010,.0035)	5008	.0030 (.0020,.0053)	305	.0020 (.0007,.0040)	288	.0019 (.0009,.0033)
3109	.0019 (.0010,.0034)	5417	.0030 (.0020,.0053)	325	.0020 (.0007,.0040)	300	.0018 (.0009,.0033)
3364	.0018 (.0009,.0033)	5444	.0030 (.0020,.0053)	347	.0019 (.0007,.0039)	313	.0018 (.0009,.0032)
3640	.0017 (.0009,.0033)	5860	.0029 (.0019,.0054)	370	.0019 (.0006,.0039)	327	.0018 (.0008,.0032)
3939	.0016 (.0008,.0032)	6339	.0028 (.0018,.0054)	395	.0018 (.0006,.0039)	341	.0017 (.0008,.0032)
4263	.0016 (.0008,.0032)	6857	.0028 (.0018,.0054)	422	.0018 (.0006,.0039)	356	.0017 (.0008,.0032)
4613	.0015 (.0007,.0031)	7417	.0027 (.0017,.0054)	450	.0018 (.0006,.0038)	372	.0017 (.0008,.0031)
4992	.0015 (.0007,.0031)	8023	.0026 (.0016,.0054)	480	.0017 (.0005,.0038)	388	.0016 (.0007,.0031)

5401	.0014 (.0006,.0030)	8679	.0026 (.0016,.0054)	500	.0017 (.0005,.0038)	405	.0016 (.0007,.0031)
5845	.0013 (.0006,.0029)	9388	.0025 (.0015,.0054)	512	.0017 (.0005,.0038)	423	.0016 (.0007,.0031)
6325	.0013 (.0006,.0029)	10155	.0024 (.0015,.0054)	547	.0016 (.0005,.0038)	441	.0015 (.0007,.0030)
6844	.0012 (.0005,.0028)	10985	.0024 (.0014,.0054)	584	.0016 (.0005,.0037)	461	.0015 (.0006,.0030)
7407	.0012 (.0005,.0028)	11883	.0023 (.0014,.0054)	623	.0016 (.0004,.0037)	481	.0015 (.0006,.0030)
8015	.0011 (.0005,.0028)	12854	.0023 (.0013,.0054)	665	.0015 (.0004,.0037)	500	.0015 (.0006,.0030)
8673	.0011 (.0004,.0027)	13904	.0022 (.0013,.0054)	709	.0015 (.0004,.0036)	502	.0014 (.0006,.0030)
9385	.0010 (.0004,.0027)	15040	.0022 (.0012,.0055)	757	.0014 (.0004,.0036)	524	.0014 (.0006,.0029)
10156	.0010 (.0004,.0026)	16269	.0021 (.0012,.0055)	1000	.0013 (.0003,.0035)	1000	.0011 (.0003,.0026)

MOCH

Table 5.5: Controlled VE as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates). Overall cumulative incidence from 7 to 192 days post Day 29 was 0.006 in vaccine recipients compared to 0.102 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.8 to 95.3%).

Anti Spike IgG (BAU/ml)		Anti RBD IgG (BAU/ml)		Pseudovirus-nAb cID50		Pseudovirus-nAb cID80	
s	Estimate	s	Estimate	s	Estimate	s	Estimate
4.1	.4618 (-0.3675,.8650)	6.8	.7892 (.5199,.9490)	1.2	.8503 (.6195,.9322)	7.5	.9060 (.8461,.9332)
4	.4817 (-0.3071,.8672)	7	.7940 (.5359,.9491)	1	.8538 (.6353,.9327)	8	.9060 (.8461,.9332)
5	.5010 (-0.2485,.8693)	8	.7986 (.5515,.9492)	1	.8572 (.6504,.9332)	8	.9060 (.8461,.9332)
5	.5196 (-0.1919,.8715)	9	.8032 (.5666,.9493)	1	.8605 (.6650,.9336)	8	.9078 (.8511,.9338)
6	.5376 (-0.1371,.8736)	9	.8077 (.5812,.9494)	2	.8637 (.6790,.9341)	8	.9095 (.8560,.9344)
6	.5550 (-0.0843,.8757)	10	.8121 (.5953,.9495)	2	.8669 (.6925,.9345)	9	.9112 (.8607,.9349)
7	.5717 (-0.0333,.8777)	11	.8163 (.6090,.9496)	2	.8700 (.7054,.9349)	9	.9129 (.8653,.9355)
7	.5879 (.0159,.8797)	12	.8205 (.6223,.9497)	2	.8730 (.7177,.9354)	9	.9146 (.8697,.9360)
8	.6035 (.0632,.8817)	13	.8246 (.6352,.9498)	2	.8760 (.7296,.9358)	10	.9162 (.8739,.9365)
8	.6186 (.1087,.8836)	14	.8286 (.6476,.9499)	2	.8789 (.7410,.9363)	10	.9178 (.8781,.9371)
9	.6331 (.1525,.8855)	15	.8325 (.6597,.9500)	2	.8817 (.7520,.9367)	11	.9193 (.8821,.9376)
10	.6471 (.1945,.8874)	16	.8364 (.6713,.9501)	2	.8845 (.7625,.9371)	11	.9209 (.8859,.9381)
11	.6606 (.2347,.8892)	18	.8401 (.6826,.9501)	3	.8872 (.7725,.9375)	12	.9224 (.8897,.9386)
11	.6736 (.2733,.8911)	19	.8438 (.6935,.9502)	3	.8898 (.7822,.9380)	12	.9239 (.8933,.9392)
12	.6861 (.3103,.8928)	20	.8473 (.7041,.9503)	3	.8924 (.7914,.9384)	13	.9253 (.8968,.9397)
13	.6982 (.3457,.8946)	22	.8508 (.7143,.9504)	3	.8949 (.8003,.9388)	13	.9267 (.9001,.9403)
15	.7099 (.3795,.8963)	24	.8542 (.7242,.9504)	3	.8974 (.8088,.9392)	14	.9281 (.9032,.9409)
16	.7211 (.4118,.8980)	26	.8576 (.7337,.9505)	4	.8998 (.8170,.9396)	14	.9295 (.9062,.9416)
17	.7319 (.4426,.8997)	28	.8608 (.7430,.9506)	4	.9021 (.8248,.9400)	15	.9308 (.9091,.9422)
18	.7423 (.4720,.9013)	30	.8640 (.7519,.9506)	4	.9044 (.8323,.9404)	15	.9315 (.9105,.9425)
20	.7523 (.5001,.9030)	33	.8671 (.7605,.9507)	4	.9066 (.8395,.9408)	16	.9322 (.9119,.9428)
22	.7619 (.5268,.9046)	36	.8702 (.7689,.9508)	5	.9088 (.8463,.9412)	16	.9334 (.9147,.9434)
23	.7712 (.5522,.9061)	38	.8732 (.7770,.9508)	5	.9110 (.8529,.9416)	17	.9347 (.9173,.9440)
25	.7801 (.5764,.9077)	42	.8761 (.7847,.9509)	5	.9130 (.8592,.9420)	18	.9360 (.9199,.9446)
27	.7887 (.5994,.9092)	45	.8789 (.7923,.9509)	6	.9151 (.8653,.9424)	18	.9372 (.9223,.9454)
30	.7970 (.6212,.9107)	49	.8817 (.7996,.9510)	6	.9164 (.8691,.9427)	19	.9384 (.9247,.9464)
32	.8050 (.6420,.9122)	53	.8844 (.8066,.9510)	6	.9171 (.8711,.9428)	20	.9395 (.9270,.9474)
35	.8126 (.6617,.9136)	57	.8871 (.8134,.9511)	7	.9190 (.8766,.9432)	21	.9407 (.9293,.9484)
37	.8200 (.6802,.9150)	62	.8897 (.8199,.9511)	7	.9209 (.8819,.9436)	22	.9417 (.9312,.9492)
40	.8271 (.6977,.9164)	67	.8922 (.8263,.9511)	7	.9228 (.8870,.9440)	22	.9418 (.9315,.9493)
44	.8339 (.7143,.9178)	72	.8947 (.8324,.9512)	8	.9239 (.8902,.9442)	23	.9429 (.9336,.9502)
47	.8404 (.7300,.9191)	78	.8971 (.8383,.9512)	8	.9246 (.8919,.9443)	24	.9440 (.9356,.9512)
51	.8467 (.7449,.9205)	78	.8972 (.8384,.9512)	9	.9263 (.8966,.9447)	25	.9451 (.9376,.9522)
56	.8528 (.7590,.9218)	84	.8995 (.8440,.9512)	9	.9281 (.9010,.9451)	26	.9461 (.9395,.9532)
60	.8586 (.7724,.9231)	91	.9018 (.8495,.9513)	10	.9298 (.9053,.9455)	27	.9472 (.9412,.9542)
64	.8630 (.7822,.9241)	99	.9041 (.8549,.9513)	10	.9298 (.9055,.9455)	28	.9475 (.9415,.9545)
65	.8642 (.7851,.9243)	107	.9063 (.8600,.9513)	10	.9314 (.9094,.9458)	28	.9482 (.9425,.9552)
70	.8696 (.7970,.9256)	115	.9085 (.8650,.9513)	11	.9330 (.9133,.9462)	30	.9492 (.9438,.9563)
76	.8748 (.8084,.9268)	125	.9106 (.8698,.9514)	12	.9346 (.9171,.9466)	31	.9501 (.9450,.9573)
82	.8797 (.8191,.9280)	125	.9106 (.8699,.9514)	13	.9361 (.9206,.9469)	32	.9511 (.9461,.9583)
84	.8812 (.8224,.9284)	135	.9126 (.8744,.9514)	13	.9376 (.9240,.9473)	34	.9520 (.9472,.9593)
89	.8845 (.8293,.9292)	146	.9147 (.8788,.9514)	14	.9386 (.9259,.9475)	35	.9527 (.9479,.9600)
96	.8891 (.8389,.9304)	158	.9166 (.8830,.9514)	14	.9391 (.9269,.9476)	35	.9529 (.9481,.9602)
104	.8935 (.8479,.9315)	171	.9185 (.8870,.9514)	15	.9405 (.9297,.9481)	37	.9538 (.9490,.9611)
113	.8978 (.8563,.9326)	185	.9204 (.8909,.9514)	16	.9419 (.9323,.9491)	38	.9547 (.9499,.9620)
121	.9011 (.8629,.9336)	188	.9208 (.8917,.9514)	17	.9433 (.9349,.9506)	40	.9556 (.9507,.9629)
122	.9018 (.8643,.9338)	200	.9223 (.8947,.9514)	19	.9446 (.9374,.9521)	42	.9564 (.9515,.9638)

132	.9057 (.8719,.9349)	216	.9241 (.8983,.9514)	19	.9447 (.9375,.9522)	43	.9570 (.9520,.9643)
143	.9095 (.8790,.9359)	234	.9258 (.9018,.9514)	20	.9459 (.9394,.9536)	44	.9573 (.9523,.9646)
155	.9131 (.8857,.9370)	253	.9275 (.9052,.9514)	21	.9472 (.9408,.9552)	45	.9581 (.9530,.9654)
168	.9166 (.8921,.9380)	274	.9292 (.9085,.9514)	23	.9484 (.9421,.9570)	47	.9589 (.9534,.9663)
181	.9199 (.8981,.9390)	296	.9309 (.9116,.9514)	24	.9497 (.9431,.9587)	50	.9597 (.9539,.9672)
196	.9231 (.9038,.9401)	320	.9325 (.9147,.9514)	24	.9497 (.9431,.9587)	52	.9604 (.9542,.9681)
212	.9262 (.9092,.9411)	347	.9340 (.9176,.9514)	26	.9508 (.9442,.9603)	54	.9612 (.9546,.9690)
224	.9282 (.9127,.9418)	375	.9355 (.9204,.9514)	27	.9520 (.9452,.9619)	56	.9619 (.9550,.9698)
230	.9292 (.9143,.9422)	376	.9356 (.9206,.9514)	29	.9531 (.9459,.9634)	59	.9627 (.9554,.9706)
249	.9320 (.9190,.9432)	406	.9370 (.9232,.9514)	30	.9537 (.9463,.9642)	61	.9634 (.9557,.9714)
269	.9347 (.9234,.9442)	439	.9385 (.9258,.9514)	31	.9542 (.9466,.9649)	63	.9637 (.9559,.9718)
291	.9373 (.9275,.9451)	474	.9399 (.9284,.9514)	33	.9553 (.9473,.9663)	64	.9641 (.9561,.9722)
315	.9398 (.9314,.9474)	500	.9409 (.9300,.9514)	36	.9564 (.9480,.9676)	67	.9648 (.9565,.9730)
333	.9415 (.9339,.9491)	513	.9413 (.9308,.9514)	38	.9574 (.9487,.9689)	70	.9654 (.9568,.9738)
341	.9423 (.9348,.9499)	555	.9427 (.9332,.9516)	41	.9584 (.9494,.9702)	73	.9661 (.9572,.9746)
369	.9446 (.9375,.9524)	601	.9440 (.9355,.9519)	43	.9594 (.9501,.9713)	74	.9663 (.9573,.9748)
399	.9468 (.9402,.9549)	603	.9441 (.9356,.9519)	45	.9601 (.9505,.9722)	76	.9667 (.9575,.9754)
432	.9489 (.9427,.9574)	650	.9453 (.9377,.9521)	46	.9603 (.9507,.9725)	79	.9674 (.9579,.9761)
468	.9510 (.9450,.9599)	703	.9466 (.9398,.9530)	49	.9613 (.9513,.9736)	83	.9680 (.9582,.9768)
475	.9514 (.9454,.9603)	760	.9478 (.9419,.9541)	53	.9622 (.9517,.9747)	87	.9686 (.9586,.9775)
500	.9527 (.9466,.9618)	822	.9490 (.9437,.9555)	55	.9628 (.9521,.9755)	90	.9692 (.9589,.9782)
506	.9530 (.9469,.9622)	889	.9502 (.9450,.9570)	56	.9631 (.9522,.9758)	90	.9692 (.9589,.9782)
548	.9549 (.9487,.9643)	912	.9506 (.9453,.9574)	60	.9639 (.9527,.9769)	94	.9698 (.9593,.9789)
593	.9567 (.9504,.9664)	962	.9514 (.9459,.9584)	64	.9648 (.9532,.9779)	98	.9704 (.9596,.9795)
641	.9584 (.9521,.9683)	1000	.9519 (.9463,.9591)	68	.9656 (.9537,.9789)	103	.9710 (.9599,.9801)
693	.9601 (.9536,.9701)	1041	.9525 (.9468,.9598)	71	.9662 (.9540,.9795)	107	.9715 (.9603,.9807)
694	.9601 (.9536,.9701)	1126	.9536 (.9475,.9611)	73	.9664 (.9541,.9798)	112	.9721 (.9606,.9814)
751	.9617 (.9545,.9718)	1218	.9547 (.9480,.9624)	78	.9672 (.9546,.9807)	117	.9726 (.9609,.9820)
813	.9632 (.9553,.9734)	1317	.9557 (.9484,.9637)	83	.9680 (.9551,.9816)	122	.9731 (.9612,.9826)
879	.9647 (.9561,.9749)	1395	.9565 (.9487,.9646)	89	.9688 (.9555,.9824)	127	.9736 (.9615,.9831)
952	.9661 (.9569,.9764)	1425	.9567 (.9488,.9649)	94	.9695 (.9560,.9832)	133	.9741 (.9619,.9837)
1000	.9670 (.9574,.9772)	1541	.9578 (.9492,.9661)	101	.9702 (.9564,.9839)	139	.9746 (.9622,.9842)
1030	.9675 (.9577,.9777)	1667	.9587 (.9496,.9672)	108	.9709 (.9569,.9846)	145	.9751 (.9625,.9848)
1114	.9688 (.9584,.9790)	1804	.9597 (.9496,.9683)	115	.9716 (.9573,.9853)	151	.9756 (.9628,.9853)
1206	.9701 (.9591,.9802)	1951	.9606 (.9496,.9694)	123	.9723 (.9576,.9860)	158	.9761 (.9631,.9857)
1294	.9711 (.9597,.9812)	2111	.9615 (.9495,.9704)	131	.9729 (.9579,.9866)	165	.9765 (.9634,.9862)
1305	.9713 (.9598,.9813)	2283	.9624 (.9495,.9714)	140	.9736 (.9583,.9872)	172	.9770 (.9637,.9867)
1412	.9724 (.9605,.9824)	2470	.9633 (.9495,.9724)	149	.9742 (.9586,.9877)	179	.9774 (.9640,.9871)
1528	.9735 (.9611,.9834)	2671	.9642 (.9494,.9733)	159	.9748 (.9589,.9883)	187	.9778 (.9643,.9875)
1653	.9746 (.9618,.9844)	2890	.9650 (.9494,.9742)	170	.9754 (.9592,.9888)	195	.9783 (.9646,.9879)
1785	.9756 (.9624,.9853)	2891	.9650 (.9494,.9742)	181	.9760 (.9595,.9893)	204	.9787 (.9649,.9883)
1789	.9756 (.9624,.9853)	3126	.9658 (.9493,.9751)	193	.9765 (.9597,.9898)	213	.9791 (.9652,.9887)
1936	.9766 (.9630,.9861)	3381	.9666 (.9493,.9760)	206	.9771 (.9600,.9902)	222	.9795 (.9655,.9891)
2095	.9776 (.9636,.9869)	3658	.9674 (.9492,.9769)	220	.9776 (.9603,.9907)	232	.9799 (.9657,.9895)
2228	.9783 (.9641,.9875)	3957	.9681 (.9492,.9777)	235	.9782 (.9606,.9911)	242	.9803 (.9660,.9898)
2267	.9785 (.9642,.9877)	4073	.9684 (.9491,.9780)	251	.9787 (.9609,.9915)	253	.9806 (.9663,.9901)
2453	.9793 (.9648,.9884)	4280	.9689 (.9491,.9785)	267	.9792 (.9612,.9918)	264	.9810 (.9666,.9905)
2655	.9802 (.9654,.9891)	4630	.9696 (.9490,.9793)	285	.9797 (.9615,.9922)	275	.9814 (.9668,.9908)
2873	.9810 (.9660,.9897)	5008	.9703 (.9490,.9801)	305	.9802 (.9617,.9925)	288	.9817 (.9671,.9911)
3109	.9817 (.9665,.9904)	5417	.9710 (.9489,.9808)	325	.9806 (.9620,.9929)	300	.9821 (.9674,.9914)
3364	.9825 (.9671,.9909)	5444	.9710 (.9489,.9808)	347	.9811 (.9623,.9932)	313	.9824 (.9676,.9917)
3640	.9832 (.9676,.9915)	5860	.9717 (.9488,.9815)	370	.9815 (.9626,.9935)	327	.9828 (.9679,.9919)
3939	.9839 (.9682,.9920)	6339	.9723 (.9488,.9821)	395	.9820 (.9628,.9938)	341	.9831 (.9682,.9922)
4263	.9845 (.9687,.9924)	6857	.9730 (.9487,.9828)	422	.9824 (.9631,.9941)	356	.9834 (.9684,.9925)

4613	.9851 (.9692,.9929)	7417	.9736 (.9486,.9834)	450	.9828 (.9633,.9943)	372	.9837 (.9687,.9927)
4992	.9857 (.9697,.9933)	8023	.9742 (.9486,.9840)	480	.9832 (.9636,.9946)	388	.9840 (.9689,.9930)
5401	.9863 (.9702,.9937)	8679	.9748 (.9485,.9846)	500	.9835 (.9637,.9947)	405	.9844 (.9692,.9932)
5845	.9869 (.9707,.9941)	9388	.9754 (.9484,.9852)	512	.9836 (.9638,.9948)	423	.9847 (.9695,.9934)
6325	.9874 (.9712,.9944)	10155	.9760 (.9483,.9857)	547	.9840 (.9641,.9950)	441	.9849 (.9697,.9936)
6844	.9879 (.9717,.9948)	10985	.9765 (.9483,.9862)	584	.9844 (.9643,.9953)	461	.9852 (.9699,.9938)
7407	.9884 (.9721,.9951)	11883	.9771 (.9482,.9867)	623	.9847 (.9646,.9955)	481	.9855 (.9702,.9940)
8015	.9889 (.9726,.9954)	12854	.9776 (.9481,.9872)	665	.9851 (.9648,.9957)	500	.9858 (.9704,.9942)
8673	.9893 (.9731,.9956)	13904	.9781 (.9480,.9877)	709	.9855 (.9650,.9959)	502	.9858 (.9704,.9942)
9385	.9898 (.9735,.9959)	15040	.9787 (.9479,.9881)	757	.9858 (.9653,.9960)	524	.9861 (.9707,.9944)
10156	.9902 (.9739,.9961)	16269	.9792 (.9478,.9885)	1000	.9872 (.9662,.9968)	1000	.9896 (.9741,.9966)
9.8	.6471 (.1945,.8874)		(,)		(,)		(,)
121	.9011 (.8629,.9336)	84	.8995 (.8440,.9512)	4	.8998 (.8170,.9396)	8	.9060 (.8461,.9332)
468	.9510 (.9450,.9599)	889	.9502 (.9450,.9570)	24	.9497 (.9431,.9587)	31	.9501 (.9450,.9573)

MOCHI

Table 5.6: Controlled VE with sensitivity analysis as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

Anti Spike IgG (BAU/ml)		Anti RBD IgG (BAU/ml)		Pseudovirus-nAb cID50		Pseudovirus-nAb cID80	
s	Estimate	s	Estimate	s	Estimate	s	Estimate
4.1	.6867 (.2040,.9214)	6.8	.8673 (.6977,.9679)	1.2	.9111 (.7740,.9597)	7.5	.9158 (.8622,.9402)
4	.6941 (.2285,.9216)	7	.8687 (.7044,.9676)	1	.9116 (.7794,.9593)	8	.9158 (.8622,.9402)
5	.7013 (.2527,.9218)	8	.8702 (.7109,.9672)	1	.9121 (.7848,.9589)	8	.9158 (.8622,.9402)
5	.7084 (.2766,.9220)	9	.8717 (.7174,.9669)	1	.9126 (.7902,.9584)	8	.9169 (.8658,.9403)
6	.7155 (.3003,.9222)	9	.8731 (.7237,.9666)	2	.9131 (.7954,.9580)	8	.9179 (.8694,.9405)
6	.7224 (.3236,.9224)	10	.8746 (.7300,.9663)	2	.9137 (.8006,.9575)	9	.9190 (.8729,.9406)
7	.7292 (.3466,.9227)	11	.8760 (.7361,.9660)	2	.9143 (.8056,.9571)	9	.9201 (.8764,.9408)
7	.7359 (.3692,.9229)	12	.8775 (.7422,.9657)	2	.9148 (.8106,.9566)	9	.9212 (.8797,.9409)
8	.7425 (.3915,.9231)	13	.8789 (.7482,.9653)	2	.9154 (.8156,.9562)	10	.9222 (.8830,.9411)
8	.7489 (.4133,.9234)	14	.8804 (.7540,.9650)	2	.9160 (.8204,.9558)	10	.9233 (.8862,.9413)
9	.7553 (.4347,.9236)	15	.8818 (.7598,.9647)	2	.9166 (.8251,.9554)	11	.9243 (.8894,.9415)
10	.7615 (.4557,.9239)	16	.8832 (.7655,.9644)	2	.9172 (.8298,.9549)	11	.9254 (.8924,.9417)
11	.7677 (.4761,.9242)	18	.8847 (.7711,.9640)	3	.9179 (.8344,.9545)	12	.9265 (.8955,.9419)
11	.7737 (.4961,.9245)	19	.8861 (.7765,.9637)	3	.9185 (.8389,.9541)	12	.9275 (.8984,.9421)
12	.7796 (.5156,.9247)	20	.8875 (.7819,.9634)	3	.9192 (.8434,.9537)	13	.9286 (.9013,.9423)
13	.7854 (.5347,.9250)	22	.8889 (.7872,.9630)	3	.9199 (.8478,.9533)	13	.9296 (.9040,.9426)
15	.7911 (.5532,.9253)	24	.8903 (.7924,.9627)	3	.9206 (.8520,.9530)	14	.9307 (.9066,.9430)
16	.7966 (.5712,.9257)	26	.8917 (.7975,.9624)	4	.9213 (.8562,.9526)	14	.9317 (.9092,.9434)
17	.8021 (.5887,.9260)	28	.8931 (.8025,.9620)	4	.9220 (.8604,.9522)	15	.9328 (.9116,.9438)
18	.8075 (.6056,.9263)	30	.8945 (.8075,.9617)	4	.9227 (.8644,.9519)	15	.9333 (.9128,.9440)
20	.8127 (.6221,.9267)	33	.8959 (.8123,.9614)	4	.9235 (.8684,.9515)	16	.9338 (.9141,.9442)
22	.8179 (.6380,.9270)	36	.8972 (.8171,.9610)	5	.9242 (.8723,.9512)	16	.9348 (.9164,.9446)
23	.8229 (.6535,.9274)	38	.8986 (.8217,.9607)	5	.9250 (.8762,.9509)	17	.9359 (.9188,.9450)
25	.8279 (.6684,.9277)	42	.9000 (.8263,.9604)	5	.9258 (.8800,.9506)	18	.9369 (.9210,.9454)
27	.8327 (.6828,.9281)	45	.9014 (.8308,.9600)	6	.9267 (.8837,.9503)	18	.9379 (.9233,.9461)
30	.8375 (.6968,.9285)	49	.9027 (.8352,.9597)	6	.9272 (.8860,.9501)	19	.9390 (.9255,.9470)
32	.8421 (.7102,.9289)	53	.9041 (.8395,.9593)	6	.9275 (.8873,.9500)	20	.9400 (.9276,.9478)
35	.8467 (.7232,.9293)	57	.9054 (.8437,.9590)	7	.9283 (.8908,.9497)	21	.9410 (.9297,.9487)
37	.8511 (.7356,.9297)	62	.9068 (.8479,.9587)	7	.9292 (.8943,.9495)	22	.9419 (.9315,.9494)
40	.8555 (.7474,.9302)	67	.9081 (.8519,.9583)	7	.9301 (.8978,.9493)	22	.9421 (.9317,.9495)
44	.8598 (.7588,.9306)	72	.9095 (.8559,.9580)	8	.9307 (.8999,.9492)	23	.9431 (.9337,.9504)
47	.8639 (.7697,.9311)	78	.9108 (.8598,.9577)	8	.9310 (.9011,.9491)	24	.9441 (.9357,.9513)
51	.8680 (.7803,.9315)	78	.9108 (.8599,.9577)	9	.9319 (.9044,.9489)	25	.9451 (.9376,.9522)
56	.8720 (.7905,.9320)	84	.9121 (.8636,.9574)	9	.9329 (.9076,.9488)	26	.9462 (.9395,.9532)
60	.8759 (.8002,.9325)	91	.9135 (.8674,.9570)	10	.9339 (.9108,.9486)	27	.9472 (.9412,.9542)
64	.8789 (.8075,.9329)	99	.9148 (.8711,.9567)	10	.9339 (.9110,.9486)	28	.9475 (.9415,.9545)
65	.8797 (.8096,.9330)	107	.9161 (.8747,.9564)	10	.9348 (.9139,.9485)	28	.9482 (.9425,.9552)
70	.8834 (.8186,.9335)	115	.9174 (.8782,.9561)	11	.9359 (.9170,.9485)	30	.9491 (.9437,.9563)
76	.8871 (.8273,.9340)	125	.9187 (.8816,.9558)	12	.9369 (.9200,.9484)	31	.9501 (.9449,.9572)
82	.8907 (.8356,.9346)	125	.9188 (.8818,.9558)	13	.9379 (.9229,.9484)	32	.9510 (.9460,.9582)
84	.8917 (.8381,.9347)	135	.9200 (.8850,.9555)	13	.9390 (.9257,.9484)	34	.9518 (.9469,.9591)
89	.8941 (.8435,.9351)	146	.9213 (.8883,.9552)	14	.9397 (.9273,.9485)	35	.9525 (.9476,.9598)
96	.8975 (.8512,.9357)	158	.9226 (.8915,.9549)	14	.9401 (.9281,.9485)	35	.9527 (.9478,.9600)
104	.9009 (.8584,.9362)	171	.9239 (.8945,.9546)	15	.9412 (.9305,.9488)	37	.9535 (.9486,.9608)
113	.9041 (.8653,.9368)	185	.9252 (.8975,.9543)	16	.9424 (.9329,.9495)	38	.9543 (.9494,.9617)
121	.9067 (.8707,.9373)	188	.9255 (.8981,.9543)	17	.9435 (.9352,.9508)	40	.9550 (.9501,.9625)
122	.9073 (.8719,.9374)	200	.9265 (.9004,.9541)	19	.9447 (.9375,.9522)	42	.9558 (.9508,.9632)
132	.9104 (.8782,.9381)	216	.9278 (.9033,.9538)	19	.9448 (.9376,.9523)	43	.9562 (.9512,.9637)
143	.9134 (.8842,.9387)	234	.9291 (.9061,.9536)	20	.9460 (.9394,.9536)	44	.9565 (.9515,.9640)

155	.9164 (.8900,.9393)	253	.9303 (.9089,.9533)	21	.9472 (.9408,.9552)	45	.9572 (.9520,.9647)
168	.9193 (.8956,.9400)	274	.9316 (.9116,.9531)	23	.9484 (.9420,.9569)	47	.9579 (.9523,.9654)
181	.9221 (.9009,.9407)	296	.9329 (.9142,.9528)	24	.9496 (.9430,.9586)	50	.9585 (.9525,.9663)
196	.9248 (.9060,.9414)	320	.9341 (.9168,.9526)	24	.9496 (.9430,.9586)	52	.9592 (.9527,.9670)
212	.9275 (.9108,.9422)	347	.9354 (.9193,.9525)	26	.9506 (.9439,.9602)	54	.9598 (.9530,.9678)
224	.9293 (.9140,.9427)	375	.9367 (.9218,.9523)	27	.9516 (.9447,.9616)	56	.9604 (.9531,.9686)
230	.9301 (.9155,.9430)	376	.9367 (.9219,.9523)	29	.9526 (.9453,.9630)	59	.9610 (.9533,.9693)
249	.9327 (.9199,.9438)	406	.9379 (.9243,.9521)	30	.9530 (.9455,.9637)	61	.9615 (.9535,.9700)
269	.9352 (.9240,.9446)	439	.9392 (.9266,.9520)	31	.9535 (.9457,.9643)	63	.9618 (.9536,.9703)
291	.9376 (.9279,.9454)	474	.9404 (.9290,.9518)	33	.9543 (.9462,.9655)	64	.9621 (.9537,.9707)
315	.9400 (.9316,.9475)	500	.9412 (.9305,.9517)	36	.9551 (.9465,.9667)	67	.9626 (.9538,.9713)
333	.9416 (.9340,.9492)	513	.9416 (.9312,.9517)	38	.9558 (.9469,.9678)	70	.9632 (.9540,.9721)
341	.9423 (.9348,.9500)	555	.9429 (.9335,.9518)	41	.9566 (.9472,.9688)	73	.9637 (.9541,.9728)
369	.9446 (.9375,.9524)	601	.9441 (.9356,.9520)	43	.9572 (.9474,.9698)	74	.9638 (.9541,.9730)
399	.9468 (.9402,.9549)	603	.9442 (.9357,.9520)	45	.9577 (.9476,.9705)	76	.9642 (.9542,.9734)
432	.9489 (.9427,.9574)	650	.9454 (.9378,.9521)	46	.9579 (.9477,.9708)	79	.9647 (.9544,.9741)
468	.9509 (.9449,.9598)	703	.9466 (.9399,.9530)	49	.9585 (.9478,.9717)	83	.9651 (.9545,.9747)
475	.9513 (.9454,.9603)	760	.9478 (.9419,.9541)	53	.9591 (.9478,.9726)	87	.9656 (.9546,.9754)
500	.9525 (.9465,.9617)	822	.9490 (.9437,.9554)	55	.9595 (.9478,.9733)	90	.9661 (.9547,.9760)
506	.9528 (.9468,.9621)	889	.9502 (.9449,.9569)	56	.9596 (.9478,.9735)	90	.9661 (.9547,.9760)
548	.9546 (.9484,.9641)	912	.9505 (.9452,.9574)	60	.9602 (.9478,.9745)	94	.9665 (.9548,.9765)
593	.9563 (.9500,.9661)	962	.9513 (.9458,.9583)	64	.9607 (.9477,.9753)	98	.9669 (.9549,.9771)
641	.9580 (.9516,.9680)	1000	.9518 (.9462,.9590)	68	.9611 (.9476,.9761)	103	.9674 (.9550,.9776)
693	.9595 (.9529,.9697)	1041	.9523 (.9466,.9596)	71	.9614 (.9476,.9767)	107	.9678 (.9550,.9782)
694	.9595 (.9529,.9697)	1126	.9533 (.9472,.9609)	73	.9616 (.9476,.9769)	112	.9682 (.9551,.9788)
751	.9610 (.9537,.9713)	1218	.9543 (.9475,.9621)	78	.9621 (.9474,.9777)	117	.9686 (.9552,.9793)
813	.9624 (.9543,.9728)	1317	.9552 (.9478,.9633)	83	.9625 (.9473,.9784)	122	.9690 (.9552,.9799)
879	.9637 (.9549,.9742)	1395	.9559 (.9480,.9641)	89	.9629 (.9472,.9791)	127	.9693 (.9553,.9804)
952	.9650 (.9555,.9756)	1425	.9561 (.9481,.9644)	94	.9633 (.9470,.9797)	133	.9697 (.9553,.9809)
1000	.9658 (.9558,.9764)	1541	.9570 (.9483,.9655)	101	.9637 (.9468,.9804)	139	.9701 (.9554,.9814)
1030	.9662 (.9560,.9769)	1667	.9579 (.9485,.9665)	108	.9640 (.9466,.9810)	145	.9704 (.9554,.9819)
1114	.9674 (.9566,.9781)	1804	.9587 (.9483,.9675)	115	.9644 (.9464,.9816)	151	.9708 (.9555,.9824)
1206	.9685 (.9570,.9792)	1951	.9594 (.9481,.9685)	123	.9647 (.9461,.9821)	158	.9711 (.9555,.9828)
1294	.9695 (.9574,.9801)	2111	.9602 (.9478,.9694)	131	.9650 (.9457,.9827)	165	.9715 (.9555,.9833)
1305	.9696 (.9574,.9802)	2283	.9609 (.9475,.9703)	140	.9653 (.9452,.9832)	172	.9718 (.9555,.9837)
1412	.9706 (.9578,.9812)	2470	.9616 (.9472,.9711)	149	.9656 (.9448,.9837)	179	.9721 (.9556,.9841)
1528	.9716 (.9582,.9822)	2671	.9623 (.9468,.9719)	159	.9659 (.9444,.9842)	187	.9724 (.9556,.9845)
1653	.9725 (.9586,.9831)	2890	.9630 (.9465,.9727)	170	.9662 (.9439,.9846)	195	.9727 (.9556,.9849)
1785	.9734 (.9590,.9839)	2891	.9630 (.9464,.9727)	181	.9665 (.9434,.9851)	204	.9730 (.9556,.9853)
1789	.9734 (.9590,.9839)	3126	.9636 (.9461,.9735)	193	.9667 (.9429,.9855)	213	.9733 (.9556,.9856)
1936	.9743 (.9593,.9847)	3381	.9642 (.9457,.9743)	206	.9670 (.9424,.9859)	222	.9736 (.9556,.9860)
2095	.9751 (.9597,.9855)	3658	.9648 (.9453,.9751)	220	.9672 (.9418,.9863)	232	.9739 (.9556,.9863)
2228	.9757 (.9599,.9861)	3957	.9654 (.9448,.9758)	235	.9675 (.9413,.9867)	242	.9742 (.9556,.9867)
2267	.9759 (.9600,.9862)	4073	.9656 (.9447,.9761)	251	.9677 (.9407,.9871)	253	.9745 (.9556,.9870)
2453	.9767 (.9603,.9869)	4280	.9660 (.9444,.9765)	267	.9679 (.9401,.9874)	264	.9747 (.9555,.9873)
2655	.9774 (.9606,.9876)	4630	.9666 (.9439,.9772)	285	.9681 (.9395,.9878)	275	.9750 (.9555,.9876)
2873	.9781 (.9609,.9882)	5008	.9671 (.9434,.9779)	305	.9683 (.9389,.9881)	288	.9753 (.9555,.9879)
3109	.9788 (.9611,.9888)	5417	.9676 (.9429,.9785)	325	.9685 (.9383,.9884)	300	.9755 (.9555,.9882)
3364	.9795 (.9614,.9894)	5444	.9676 (.9429,.9786)	347	.9687 (.9376,.9887)	313	.9758 (.9554,.9885)
3640	.9801 (.9617,.9899)	5860	.9681 (.9424,.9792)	370	.9689 (.9370,.9890)	327	.9760 (.9554,.9888)
3939	.9807 (.9619,.9904)	6339	.9686 (.9419,.9797)	395	.9691 (.9363,.9893)	341	.9763 (.9554,.9891)
4263	.9813 (.9621,.9909)	6857	.9691 (.9413,.9803)	422	.9693 (.9356,.9896)	356	.9765 (.9553,.9893)
4613	.9818 (.9624,.9913)	7417	.9696 (.9408,.9809)	450	.9694 (.9348,.9899)	372	.9768 (.9553,.9896)
4992	.9824 (.9626,.9917)	8023	.9700 (.9402,.9814)	480	.9696 (.9341,.9902)	388	.9770 (.9552,.9898)

5401	.9829 (.9628,.9921)	8679	.9705 (.9396,.9819)	500	.9697 (.9336,.9903)	405	.9772 (.9552,.9901)
5845	.9834 (.9630,.9925)	9388	.9709 (.9389,.9824)	512	.9698 (.9333,.9904)	423	.9775 (.9551,.9903)
6325	.9839 (.9632,.9929)	10155	.9713 (.9383,.9829)	547	.9699 (.9325,.9907)	441	.9777 (.9551,.9905)
6844	.9844 (.9634,.9932)	10985	.9717 (.9376,.9834)	584	.9701 (.9317,.9909)	461	.9779 (.9550,.9908)
7407	.9848 (.9636,.9935)	11883	.9721 (.9370,.9838)	623	.9702 (.9308,.9911)	481	.9781 (.9549,.9910)
8015	.9853 (.9638,.9939)	12854	.9725 (.9363,.9843)	665	.9704 (.9300,.9914)	500	.9783 (.9549,.9912)
8673	.9857 (.9639,.9942)	13904	.9729 (.9356,.9847)	709	.9705 (.9291,.9916)	502	.9783 (.9549,.9912)
9385	.9861 (.9641,.9944)	15040	.9733 (.9348,.9851)	757	.9707 (.9282,.9918)	524	.9785 (.9548,.9914)
10156	.9865 (.9642,.9947)	16269	.9737 (.9341,.9855)	1000	.9712 (.9242,.9927)	1000	.9813 (.9535,.9940)
9.8	.6471 (.1945,.8874)		(,)		(,)		(,)
121	.9011 (.8629,.9336)	84	.8995 (.8440,.9512)	4	.8998 (.8170,.9396)	8	.9060 (.8461,.9332)
468	.9510 (.9450,.9599)	889	.9502 (.9450,.9570)	24	.9497 (.9431,.9587)	31	.9501 (.9450,.9573)

MOCY

5.3 Misc

Average follow-up of vaccine recipients (in the D29 correlates analyses population) starting at 7 days post Day 29 visit (not counting the 7 days) is 193 days.




Figure 5.12: Distribution of the number of days between visits in the per-protocol immunogenicity subcohort, vaccine arm, baseline negative. The median (IQR) number of days between Day 1 and Day 29 was 29 (27-31).

Table 5.7: Deciles of Day 29 cID50 titer for the immunogenicity subcohort in the vaccine arm.

	min	10%	20%	30%	40%	50%	60%	70%	80%	90%	max
Baseline negative											
All	1	4	8	11	14	18	24	29	39	59	757
Age ≥ 65 , URM	1	9	12	17	21	27	35	44	61	88	312
Age < 65 , At risk, URM	1	5	8	10	11	16	18	27	35	50	101
Age < 65 , Not at risk, URM	1	6	9	13	15	22	25	29	37	55	207
Age ≥ 65 , White non-Hisp	4	9	12	17	24	29	34	43	60	99	757
Age < 65 , At risk, White non-Hisp	1	4	8	10	14	18	21	25	30	46	81
Age < 65 , Not at risk, White non-Hisp	1	3	5	10	12	13	18	27	34	59	211
Baseline positive											
All	3	9	14	19	25	32	37	53	71	134	1141
Age ≥ 65 , URM	11	17	24	30	51	74	82	103	165	274	1141
Age < 65 , At risk, URM	3	6	10	15	16	24	31	36	52	132	372
Age < 65 , Not at risk, URM	8	13	14	16	22	24	34	42	65	124	152
Age ≥ 65 , White non-Hisp	7	21	26	35	40	50	65	80	105	152	438
Age < 65 , At risk, White non-Hisp	6	10	13	16	21	30	37	47	56	66	222
Age < 65 , Not at risk, White non-Hisp	5	8	13	18	26	30	34	39	67	134	215

Table 5.8: Summary statistics for the number of days from dose 1 to Day 29 visit. (a) The whole immunogenicity subcohort, (b) non-cases in the immunogenicity subcohort, (c) intercurrent cases, (d) primary cases, i.e. cases from the Day 57 correlates analysis population.

	min	1st quartile	median	3rd quartile	max
(a)	26	27	29	31	32
(b)	26	28	29	31	32
(c)	26	28	30	30	32
(d)	26	28	29	31	32

MOCK

Chapter 6

Day D57 Univariate CoR: Cox Models of Risk

The main regression model is the Cox proportional hazards model. All plots are made with Cox models fit unless specified otherwise.

6.1 Hazard ratios

Table 6.1: Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*

MockCOVE Immunologic Marker	No. cases / No. at-risk**	HR per 10-fold incr. Pt. Est.	P-value 95% CI (2-sided)	q-value ***	FWER
Anti Spike IgG (BAU/ml)	52/11,117	0.20	(0.11-0.36)	<0.001	<0.001 <0.001
Anti RBD IgG (BAU/ml)	52/11,117	0.43	(0.25-0.74)	0.003	<0.001 <0.001
Pseudovirus-nAb cID50	52/11,117	0.32	(0.17-0.60)	<0.001	<0.001 <0.001
Pseudovirus-nAb cID80	52/11,117	0.34	(0.18-0.63)	<0.001	<0.001 <0.001

*Baseline covariates adjusted for: baseline risk score, meeting the protocol randomization stratification criterion for being at heightened risk of COVID (yes or no), community of color or not. Maximum failure event time 164 days.

**No. at-risk = estimated number in the population for analysis: baseline negative per-protocol vaccine recipients not experiencing the COVID endpoint through 6 days post Day 57 visit; no. cases = number of this cohort with an observed COVID endpoint.

***q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers using the Westfall and Young permutation method (10 replicates).

Table 6.2: Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*

MockCOVE Immunologic Marker	Tertile	No. cases / No. at-risk**	Attack rate	Pt. Est.	Haz. Ratio 95% CI	P-value (2-sided)	Overall P- value***	Overall q- value †	Overall FWER
Anti Spike IgG (BAU/ml)	Lower	27/4,235	0.0064	1	N/A	N/A	<0.001	<0.001	<0.001
	Middle	18/4,243	0.0042	0.30	(0.16-0.58)	<0.001			
	Upper	7/2,638	0.0027	0.08	(0.03-0.21)	<0.001			
Anti RBD IgG (BAU/ml)	Lower	24/4,242	0.0057	1	N/A	N/A	0.003	<0.001	<0.001
	Middle	14/4,209	0.0033	0.32	(0.15-0.70)	0.004			
	Upper	14/2,666	0.0053	0.29	(0.13-0.63)	0.002			
Pseudovirus-nAb cID50	Lower	18/3,697	0.0049	1	N/A	N/A	0.035	<0.001	<0.001
	Middle	20/3,701	0.0054	0.80	(0.39-1.64)	0.546			
	Upper	14/3,719	0.0038	0.37	(0.16-0.82)	0.015			
Pseudovirus-nAb cID80	Lower	22/3,724	0.0059	1	N/A	N/A	0.009	<0.001	<0.001
	Middle	20/3,707	0.0054	0.66	(0.34-1.26)	0.206			
	Upper	10/3,687	0.0027	0.29	(0.13-0.64)	0.002			
Placebo		953/11,217	0.0850						

*Baseline covariates adjusted for: baseline risk score, meeting the protocol randomization stratification criterion for being at heightened risk of COVID (yes or no), community of color or not. Maximum failure event time 164 days. Cutpoints: Anti Spike IgG (BAU/ml) [3.34, 4.01], Anti RBD IgG (BAU/ml) [3.48, 4.21], Pseudovirus-nAb cID50 [2.37, 2.86], Pseudovirus-nAb cID80 [2.58, 2.96], all on the log10 scale.

**No. at-risk = estimated number in the population for analysis: baseline negative per-protocol vaccine recipients not experiencing the COVID endpoint through 6 days post Day 57 visit; no. cases = number of this cohort with an observed COVID endpoint.

***Generalized Wald-test p-value of the null hypothesis that the hazard rate is constant across the Lower, Middle, and Upper tertile groups.

† q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers using the Westfall and Young permutation method (10 replicates).




Figure 6.1: Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals.

Binding Antibody to Spike: Day 57




Figure 6.2: Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to spike markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

Binding Antibody to RBD: Day 57




Figure 6.3: Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

PsV Neutralization 50% Titer: Day 57




Figure 6.4: Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

PsV Neutralization 80% Titer: Day 57




Figure 6.5: Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and different subpopulations with 95% point-wise confidence intervals.

6.2 Marginalized risk and controlled vaccine efficacy plots

MOCK

Table 6.3: Analysis of Day 57 markers (upper vs. lower tertile) as a CoR and a controlled risk CoP.

	marginalized risk			controlled risk		
	ratio $RR_M(0, 1)$	Point Est.	95% CI	ratio $RR_C(0, 1)^1$	Point Est.	95% CI
Anti Spike IgG (BAU/ml)	0.09	0.04–0.19	0.11	0.06–0.25	22.8	10.2
Anti RBD IgG (BAU/ml)	0.29	0.11–0.46	0.39	0.15–0.62	6.4	3.8
Pseudovirus-nAb cID50	0.37	0.24–0.54	0.49	0.32–0.72	4.9	3.1
Pseudovirus-nAb cID80	0.29	0.14–0.66	0.39	0.18–0.88	6.3	2.4

¹Conservative (upper bound) estimate assuming unmeasured confounding at level $RR_{UD}(0, 1) = RR_{EU}(0, 1) = 2$ and thus $B(0, 1) = 4/3$.

²E-values are computed for upper tertile ($s = 1$) vs. lower tertile ($s = 0$) biomarker subgroups after controlling for baseline risk score, meeting the protocol randomization stratification criterion for being at heightened risk of COVID (yes or no), community of color or not; UL = upper limit.




Figure 6.6: Marginalized cumulative incidence rate curves for trichotomized Day 57 markers among baseline negative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.




Figure 6.7: Marginalized cumulative risk by Day 164 as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.




Figure 6.8: Controlled VE with sensitivity analysis as functions of Day 57 markers ($=s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $l_{od} = 0.3$ for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.




Figure 6.9: Controlled VE with sensitivity analysis as functions of Day 57 markers ($=s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3 for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.




Figure 6.10: Marginalized cumulative risk by Day 164 post Day 57 visit as functions of Day 57 markers above a threshold ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required, 10 replicates). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 0.3$ for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.




Figure 6.11: Controlled VE as functions of Day 57 markers ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (10 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 0.3$ for bAb Spike, 1.6 for bAb RBD, 2.4 for PsV nAb ID50, 15 for PsV nAb ID80, respectively.

Table 6.4: Marginalized cumulative risk by Day 164 as functions of Day 57 markers ($=s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

Anti Spike IgG (BAU/ml)		Anti RBD IgG (BAU/ml)		Pseudovirus-nAb cID50		Pseudovirus-nAb cID80	
s	Estimate	s	Estimate	s	Estimate	s	Estimate
20.7	.1334 (.0442,.3655)	11.8	.0418 (.0159,.1741)	13.7	.0264 (.0149,.0498)	25.3	.0197 (.0070,.0362)
22	.1290 (.0431,.3558)	13	.0407 (.0157,.1686)	15	.0256 (.0146,.0479)	27	.0192 (.0069,.0348)
23	.1248 (.0420,.3462)	14	.0397 (.0155,.1632)	16	.0248 (.0143,.0460)	29	.0186 (.0068,.0333)
25	.1206 (.0409,.3367)	15	.0387 (.0153,.1579)	17	.0240 (.0141,.0442)	31	.0181 (.0067,.0320)
27	.1166 (.0399,.3273)	16	.0378 (.0151,.1528)	18	.0232 (.0138,.0425)	33	.0175 (.0067,.0307)
28	.1127 (.0389,.3181)	17	.0368 (.0149,.1477)	19	.0225 (.0135,.0408)	35	.0170 (.0066,.0294)
30	.1088 (.0379,.3090)	18	.0359 (.0147,.1428)	20	.0218 (.0133,.0392)	37	.0165 (.0065,.0282)
32	.1051 (.0369,.3000)	20	.0350 (.0145,.1380)	22	.0211 (.0130,.0377)	40	.0160 (.0064,.0271)
34	.1014 (.0360,.2912)	21	.0341 (.0143,.1333)	23	.0204 (.0128,.0362)	42	.0156 (.0064,.0260)
36	.0979 (.0350,.2825)	23	.0333 (.0141,.1287)	25	.0198 (.0125,.0347)	45	.0151 (.0063,.0249)
39	.0945 (.0341,.2740)	25	.0324 (.0139,.1242)	27	.0192 (.0123,.0334)	48	.0147 (.0062,.0239)
41	.0911 (.0333,.2655)	26	.0316 (.0137,.1199)	29	.0186 (.0120,.0320)	52	.0143 (.0061,.0229)
44	.0879 (.0324,.2573)	28	.0308 (.0136,.1157)	31	.0180 (.0118,.0308)	55	.0138 (.0061,.0219)
47	.0847 (.0316,.2491)	31	.0300 (.0134,.1116)	33	.0174 (.0116,.0295)	59	.0134 (.0060,.0210)
50	.0817 (.0307,.2411)	33	.0293 (.0132,.1076)	35	.0169 (.0113,.0283)	63	.0130 (.0059,.0201)
53	.0787 (.0299,.2332)	35	.0285 (.0130,.1037)	38	.0163 (.0111,.0272)	67	.0127 (.0059,.0193)
56	.0758 (.0291,.2255)	38	.0278 (.0128,.0999)	40	.0158 (.0109,.0261)	71	.0123 (.0058,.0185)
60	.0730 (.0284,.2179)	41	.0271 (.0127,.0962)	43	.0153 (.0107,.0251)	76	.0119 (.0057,.0177)
64	.0703 (.0276,.2104)	44	.0264 (.0125,.0927)	46	.0148 (.0105,.0240)	81	.0116 (.0057,.0170)
68	.0677 (.0269,.2031)	47	.0257 (.0123,.0892)	49	.0143 (.0103,.0231)	87	.0112 (.0056,.0163)
72	.0652 (.0262,.1959)	51	.0251 (.0122,.0859)	53	.0139 (.0100,.0221)	92	.0109 (.0055,.0156)
77	.0627 (.0255,.1888)	55	.0244 (.0120,.0826)	56	.0134 (.0098,.0212)	99	.0106 (.0055,.0150)
82	.0604 (.0249,.1819)	59	.0238 (.0118,.0795)	60	.0130 (.0096,.0204)	105	.0103 (.0054,.0145)
87	.0581 (.0242,.1751)	63	.0232 (.0117,.0765)	65	.0126 (.0094,.0196)	112	.0100 (.0053,.0139)
93	.0558 (.0236,.1685)	68	.0226 (.0115,.0735)	69	.0122 (.0091,.0188)	120	.0097 (.0053,.0134)
99	.0537 (.0229,.1619)	73	.0220 (.0114,.0707)	74	.0118 (.0089,.0180)	128	.0094 (.0052,.0129)
105	.0516 (.0223,.1556)	79	.0214 (.0112,.0679)	79	.0114 (.0086,.0173)	136	.0091 (.0052,.0124)
112	.0496 (.0217,.1493)	85	.0209 (.0111,.0653)	85	.0111 (.0084,.0166)	145	.0089 (.0051,.0120)
119	.0477 (.0212,.1432)	91	.0204 (.0109,.0627)	90	.0107 (.0081,.0159)	155	.0086 (.0050,.0115)
127	.0459 (.0206,.1373)	98	.0198 (.0108,.0602)	97	.0104 (.0079,.0152)	165	.0084 (.0050,.0111)
135	.0441 (.0201,.1315)	106	.0193 (.0106,.0579)	104	.0100 (.0077,.0146)	166	.0083 (.0050,.0110)
144	.0423 (.0195,.1258)	114	.0188 (.0105,.0555)	111	.0097 (.0075,.0140)	177	.0081 (.0049,.0106)
153	.0407 (.0190,.1203)	122	.0183 (.0103,.0533)	113	.0096 (.0074,.0138)	188	.0079 (.0049,.0102)
163	.0391 (.0185,.1149)	131	.0179 (.0102,.0512)	118	.0094 (.0072,.0134)	201	.0076 (.0048,.0099)
174	.0375 (.0180,.1097)	141	.0174 (.0100,.0491)	127	.0091 (.0070,.0129)	214	.0074 (.0048,.0095)
185	.0360 (.0175,.1046)	152	.0170 (.0099,.0471)	136	.0088 (.0068,.0123)	216	.0074 (.0048,.0094)
197	.0346 (.0171,.0997)	164	.0165 (.0097,.0452)	145	.0085 (.0066,.0118)	229	.0072 (.0047,.0091)
210	.0332 (.0166,.0950)	176	.0161 (.0096,.0434)	150	.0084 (.0065,.0116)	244	.0070 (.0047,.0088)
223	.0319 (.0162,.0904)	189	.0157 (.0095,.0416)	155	.0083 (.0064,.0114)	260	.0068 (.0046,.0085)
238	.0306 (.0157,.0859)	204	.0153 (.0093,.0399)	166	.0080 (.0062,.0109)	278	.0066 (.0045,.0082)
253	.0294 (.0153,.0816)	219	.0149 (.0092,.0382)	178	.0077 (.0060,.0104)	285	.0065 (.0045,.0080)
269	.0282 (.0149,.0775)	236	.0145 (.0091,.0366)	190	.0075 (.0058,.0100)	296	.0064 (.0045,.0079)
287	.0270 (.0145,.0735)	254	.0141 (.0089,.0351)	191	.0075 (.0058,.0100)	316	.0062 (.0044,.0076)
305	.0259 (.0141,.0697)	273	.0137 (.0088,.0337)	203	.0072 (.0056,.0096)	337	.0060 (.0044,.0073)
325	.0249 (.0137,.0660)	294	.0134 (.0087,.0322)	218	.0070 (.0055,.0092)	360	.0058 (.0043,.0070)
346	.0239 (.0134,.0625)	316	.0130 (.0085,.0309)	233	.0068 (.0053,.0088)	384	.0057 (.0042,.0068)
368	.0229 (.0130,.0591)	340	.0127 (.0084,.0296)	249	.0066 (.0051,.0085)	410	.0055 (.0041,.0065)
392	.0219 (.0126,.0559)	365	.0124 (.0083,.0284)	266	.0064 (.0050,.0081)	437	.0053 (.0041,.0063)
417	.0210 (.0123,.0528)	393	.0120 (.0082,.0272)	285	.0061 (.0048,.0078)	440	.0053 (.0041,.0063)

444	.0202 (.0119,.0498)	423	.0117 (.0080,.0260)	305	.0059 (.0047,.0075)	466	.0052 (.0040,.0061)
473	.0194 (.0116,.0470)	455	.0114 (.0079,.0249)	326	.0058 (.0045,.0072)	497	.0050 (.0039,.0059)
500	.0186 (.0113,.0447)	489	.0111 (.0078,.0238)	330	.0057 (.0045,.0072)	500	.0050 (.0039,.0059)
504	.0186 (.0113,.0444)	500	.0110 (.0078,.0235)	349	.0056 (.0044,.0069)	531	.0049 (.0039,.0057)
536	.0178 (.0109,.0418)	526	.0108 (.0077,.0228)	373	.0054 (.0042,.0067)	566	.0047 (.0038,.0055)
571	.0171 (.0106,.0394)	566	.0105 (.0075,.0219)	399	.0052 (.0041,.0064)	581	.0047 (.0038,.0055)
608	.0163 (.0103,.0371)	609	.0103 (.0074,.0209)	427	.0050 (.0040,.0061)	604	.0046 (.0037,.0053)
647	.0157 (.0101,.0349)	655	.0100 (.0072,.0200)	454	.0049 (.0039,.0059)	644	.0045 (.0036,.0052)
653	.0156 (.0100,.0346)	705	.0097 (.0071,.0192)	457	.0049 (.0039,.0059)	687	.0043 (.0035,.0050)
689	.0150 (.0098,.0329)	758	.0095 (.0069,.0183)	489	.0047 (.0037,.0057)	733	.0042 (.0034,.0049)
733	.0144 (.0095,.0309)	763	.0095 (.0069,.0183)	500	.0047 (.0037,.0056)	749	.0042 (.0034,.0048)
780	.0138 (.0092,.0291)	816	.0092 (.0067,.0176)	523	.0046 (.0036,.0055)	782	.0041 (.0033,.0048)
831	.0132 (.0090,.0273)	877	.0090 (.0066,.0168)	560	.0044 (.0035,.0053)	835	.0040 (.0032,.0047)
884	.0127 (.0087,.0257)	944	.0088 (.0064,.0161)	599	.0043 (.0034,.0051)	891	.0038 (.0031,.0046)
942	.0121 (.0085,.0241)	1000	.0086 (.0063,.0155)	641	.0041 (.0033,.0049)	950	.0037 (.0030,.0045)
960	.0120 (.0084,.0237)	1015	.0085 (.0063,.0154)	673	.0040 (.0032,.0048)	958	.0037 (.0030,.0045)
1000	.0117 (.0083,.0227)	1092	.0083 (.0061,.0147)	686	.0040 (.0032,.0048)	1000	.0036 (.0029,.0044)
1002	.0116 (.0082,.0227)	1139	.0082 (.0060,.0143)	733	.0039 (.0031,.0047)	1014	.0036 (.0029,.0044)
1067	.0111 (.0080,.0213)	1175	.0081 (.0060,.0141)	785	.0038 (.0030,.0046)	1081	.0035 (.0028,.0043)
1136	.0107 (.0078,.0200)	1264	.0079 (.0058,.0135)	839	.0036 (.0029,.0045)	1154	.0034 (.0027,.0042)
1209	.0102 (.0076,.0188)	1360	.0077 (.0057,.0129)	898	.0035 (.0028,.0044)	1231	.0033 (.0026,.0041)
1288	.0098 (.0074,.0176)	1463	.0075 (.0055,.0123)	909	.0035 (.0028,.0044)	1313	.0032 (.0025,.0041)
1297	.0098 (.0073,.0175)	1573	.0073 (.0054,.0118)	961	.0034 (.0027,.0043)	1401	.0031 (.0023,.0040)
1371	.0094 (.0072,.0166)	1693	.0071 (.0053,.0113)	1000	.0033 (.0027,.0043)	1452	.0031 (.0023,.0040)
1459	.0090 (.0070,.0155)	1817	.0069 (.0051,.0108)	1028	.0033 (.0026,.0042)	1495	.0030 (.0023,.0040)
1553	.0086 (.0068,.0146)	1821	.0069 (.0051,.0108)	1100	.0032 (.0026,.0041)	1595	.0029 (.0022,.0039)
1654	.0083 (.0066,.0137)	1959	.0067 (.0050,.0103)	1177	.0031 (.0025,.0041)	1701	.0028 (.0021,.0039)
1761	.0079 (.0063,.0128)	2107	.0065 (.0049,.0099)	1259	.0030 (.0024,.0040)	1815	.0028 (.0020,.0038)
1874	.0076 (.0061,.0121)	2267	.0064 (.0048,.0094)	1347	.0029 (.0023,.0039)	1840	.0027 (.0020,.0038)
1995	.0073 (.0058,.0113)	2438	.0062 (.0047,.0090)	1441	.0028 (.0023,.0038)	1936	.0027 (.0019,.0038)
2124	.0070 (.0056,.0106)	2623	.0060 (.0046,.0086)	1491	.0027 (.0022,.0038)	2066	.0026 (.0018,.0037)
2261	.0067 (.0054,.0100)	2821	.0059 (.0044,.0083)	1541	.0027 (.0022,.0038)	2204	.0025 (.0017,.0037)
2408	.0064 (.0051,.0093)	3035	.0057 (.0043,.0079)	1649	.0026 (.0021,.0037)	2349	.0024 (.0017,.0036)
2563	.0061 (.0049,.0088)	3265	.0056 (.0042,.0076)	1764	.0025 (.0020,.0036)	2352	.0024 (.0017,.0036)
2729	.0059 (.0047,.0082)	3512	.0054 (.0041,.0073)	1887	.0024 (.0020,.0035)	2509	.0024 (.0016,.0036)
2905	.0056 (.0045,.0077)	3607	.0054 (.0041,.0071)	2019	.0024 (.0019,.0035)	2677	.0023 (.0015,.0035)
2957	.0055 (.0045,.0076)	3778	.0053 (.0040,.0070)	2027	.0024 (.0019,.0035)	2856	.0022 (.0015,.0035)
3092	.0054 (.0043,.0072)	4064	.0051 (.0039,.0067)	2160	.0023 (.0018,.0034)	3047	.0022 (.0014,.0034)
3292	.0051 (.0041,.0068)	4372	.0050 (.0038,.0064)	2311	.0022 (.0017,.0033)	3250	.0021 (.0014,.0034)
3505	.0049 (.0040,.0064)	4703	.0049 (.0037,.0061)	2440	.0022 (.0017,.0033)	3468	.0020 (.0013,.0033)
3731	.0047 (.0038,.0060)	5059	.0047 (.0036,.0059)	2472	.0021 (.0017,.0033)	3699	.0020 (.0012,.0033)
3972	.0045 (.0036,.0056)	5443	.0046 (.0036,.0057)	2645	.0021 (.0016,.0032)	3947	.0019 (.0012,.0033)
4229	.0043 (.0035,.0052)	5855	.0045 (.0035,.0055)	2830	.0020 (.0015,.0031)	4211	.0019 (.0011,.0032)
4502	.0041 (.0033,.0049)	6262	.0044 (.0034,.0053)	3028	.0019 (.0015,.0031)	4492	.0018 (.0011,.0032)
4553	.0041 (.0033,.0049)	6298	.0044 (.0034,.0053)	3239	.0019 (.0014,.0030)	4793	.0018 (.0010,.0031)
4792	.0040 (.0032,.0046)	6775	.0043 (.0033,.0051)	3465	.0018 (.0014,.0030)	5113	.0017 (.0010,.0031)
5102	.0038 (.0030,.0043)	7288	.0042 (.0032,.0049)	3707	.0018 (.0013,.0029)	5455	.0017 (.0010,.0031)
5431	.0036 (.0029,.0042)	7840	.0040 (.0031,.0048)	3966	.0017 (.0012,.0028)	5820	.0016 (.0009,.0030)
5782	.0035 (.0028,.0041)	8434	.0039 (.0031,.0047)	4243	.0016 (.0012,.0028)	6209	.0016 (.0009,.0030)
6156	.0033 (.0027,.0040)	9073	.0038 (.0030,.0046)	4540	.0016 (.0011,.0027)	6625	.0015 (.0008,.0029)
6553	.0032 (.0025,.0039)	9688	.0037 (.0029,.0046)	4857	.0015 (.0011,.0027)	7068	.0015 (.0008,.0029)
6937	.0031 (.0024,.0038)	9760	.0037 (.0029,.0046)	5196	.0015 (.0011,.0026)	7540	.0014 (.0008,.0029)
6976	.0031 (.0024,.0038)	10499	.0036 (.0028,.0045)	5559	.0014 (.0010,.0026)	8044	.0014 (.0007,.0028)
7427	.0029 (.0023,.0037)	11294	.0035 (.0027,.0045)	5947	.0014 (.0010,.0025)	8582	.0013 (.0007,.0028)

7907	.0028 (.0022,.0036)	12149	.0034 (.0026,.0044)	6362	.0014 (.0009,.0025)	9156	.0013 (.0007,.0028)
8417	.0027 (.0021,.0035)	13069	.0034 (.0026,.0043)	6807	.0013 (.0009,.0024)	9769	.0013 (.0006,.0027)
8961	.0026 (.0020,.0034)	14059	.0033 (.0025,.0043)	7282	.0013 (.0009,.0024)	10422	.0012 (.0006,.0027)
9540	.0025 (.0019,.0033)	15124	.0032 (.0024,.0042)	7791	.0012 (.0008,.0023)	11119	.0012 (.0006,.0027)
10145	.0024 (.0018,.0032)	15353	.0032 (.0024,.0042)	8335	.0012 (.0008,.0023)	11862	.0012 (.0006,.0026)
10156	.0024 (.0018,.0032)	16269	.0031 (.0023,.0042)	8917	.0011 (.0008,.0022)	12656	.0011 (.0005,.0026)
10156	.0024 (.0018,.0032)	16269	.0031 (.0023,.0042)	9540	.0011 (.0007,.0022)	13502	.0011 (.0005,.0026)
10156	.0024 (.0018,.0032)	16269	.0031 (.0023,.0042)	10206	.0011 (.0007,.0022)	14405	.0011 (.0005,.0025)
10156	.0024 (.0018,.0032)	16269	.0031 (.0023,.0042)	10919	.0010 (.0007,.0021)	15368	.0010 (.0005,.0025)

MOCY

Table 6.5: Controlled VE as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates). Overall cumulative incidence from 7 to 164 days post Day 57 was 0.005 in vaccine recipients compared to 0.090 in placebo recipients, with cumulative vaccine efficacy 94.6% (95% CI 93.7 to 95.6%).

	Anti Spike IgG (BAU/ml)	s	Anti RBD IgG (BAU/ml)	s	Pseudovirus-nAb cID50	s	Pseudovirus-nAb cID80	s
20.7	-0.4851 (-2.8670,.5056)	11.8	.5347 (-0.8521,.8226)	13.7	.7061 (.4693,.8350)	25.3	.7804 (.5922,.9207)	
22	-0.4367 (-2.7640,.5180)	13	.5463 (-0.7933,.8250)	15	.7153 (.4899,.8382)	27	.7867 (.6089,.9217)	
23	-0.3895 (-2.6622,.5301)	14	.5576 (-0.7358,.8273)	16	.7242 (.5098,.8413)	29	.7929 (.6249,.9226)	
25	-0.3434 (-2.5617,.5420)	15	.5686 (-0.6796,.8296)	17	.7329 (.5289,.8444)	31	.7989 (.6402,.9234)	
27	-0.2984 (-2.4625,.5536)	16	.5794 (-0.6246,.8319)	18	.7412 (.5473,.8474)	33	.8047 (.6549,.9243)	
28	-0.2546 (-2.3647,.5649)	17	.5900 (-0.5709,.8342)	19	.7494 (.5651,.8504)	35	.8104 (.6690,.9252)	
30	-0.2119 (-2.2683,.5760)	18	.6003 (-0.5185,.8364)	20	.7573 (.5822,.8533)	37	.8159 (.6826,.9260)	
32	-0.1703 (-2.1733,.5868)	20	.6103 (-0.4673,.8386)	22	.7649 (.5987,.8561)	40	.8213 (.6957,.9269)	
34	-0.1298 (-2.0797,.5973)	21	.6201 (-0.4174,.8408)	23	.7723 (.6145,.8589)	42	.8265 (.7082,.9277)	
36	-0.0904 (-1.9876,.6077)	23	.6297 (-0.3687,.8429)	25	.7795 (.6298,.8617)	45	.8315 (.7203,.9286)	
39	-0.0521 (-1.8970,.6178)	25	.6391 (-0.3213,.8450)	27	.7865 (.6445,.8644)	48	.8364 (.7319,.9294)	
41	-0.0148 (-1.8078,.6276)	26	.6482 (-0.2751,.8471)	29	.7932 (.6587,.8670)	52	.8412 (.7430,.9302)	
44	0.0213 (-1.7200,.6372)	28	.6571 (-0.2301,.8491)	31	.7998 (.6723,.8696)	55	.8458 (.7537,.9310)	
47	0.0564 (-1.6338,.6466)	31	.6658 (-0.1864,.8512)	33	.8061 (.6854,.8721)	59	.8503 (.7639,.9318)	
50	0.0905 (-1.5489,.6558)	33	.6743 (-0.1439,.8532)	35	.8123 (.6980,.8746)	63	.8547 (.7737,.9326)	
53	0.1236 (-1.4656,.6647)	35	.6825 (-0.1026,.8551)	38	.8182 (.7101,.8770)	67	.8589 (.7832,.9333)	
56	0.1556 (-1.3836,.6734)	38	.6906 (-0.0624,.8571)	40	.8240 (.7218,.8794)	71	.8631 (.7922,.9341)	
60	0.1867 (-1.3031,.6820)	41	.6985 (-0.0234,.8590)	43	.8296 (.7330,.8818)	76	.8671 (.8009,.9349)	
64	0.2168 (-1.2241,.6903)	44	.7062 (.0144,.8609)	46	.8350 (.7438,.8841)	81	.8709 (.8092,.9356)	
68	0.2459 (-1.1465,.6984)	47	.7137 (.0510,.8628)	49	.8403 (.7541,.8863)	87	.8747 (.8172,.9364)	
72	0.2742 (-1.0704,.7063)	51	.7210 (.0866,.8646)	53	.8454 (.7641,.8885)	92	.8784 (.8249,.9371)	
77	0.3015 (-0.9957,.7140)	55	.7281 (.1211,.8664)	56	.8503 (.7737,.8907)	99	.8820 (.8323,.9378)	
82	0.3279 (-0.9224,.7215)	59	.7351 (.1544,.8682)	60	.8551 (.7828,.8928)	105	.8854 (.8393,.9385)	
87	0.3534 (-0.8506,.7288)	63	.7418 (.1867,.8700)	65	.8597 (.7917,.8949)	112	.8888 (.8461,.9392)	
93	0.3781 (-0.7802,.7360)	68	.7485 (.2180,.8718)	69	.8642 (.8002,.8970)	120	.8920 (.8525,.9399)	
99	0.4019 (-0.7114,.7429)	73	.7549 (.2482,.8735)	74	.8685 (.8083,.8992)	128	.8952 (.8588,.9406)	
105	0.4249 (-0.6439,.7497)	79	.7612 (.2774,.8752)	79	.8727 (.8161,.9021)	136	.8983 (.8647,.9413)	
112	0.4472 (-0.5780,.7563)	85	.7673 (.3056,.8769)	85	.8768 (.8236,.9048)	145	.9013 (.8704,.9420)	
119	0.4686 (-0.5136,.7628)	91	.7733 (.3329,.8785)	90	.8807 (.8309,.9075)	155	.9042 (.8759,.9427)	
127	0.4893 (-0.4507,.7690)	98	.7792 (.3593,.8802)	97	.8845 (.8378,.9101)	165	.9070 (.8811,.9433)	
135	0.5093 (-0.3893,.7752)	106	.7849 (.3847,.8818)	104	.8882 (.8444,.9127)	166	.9071 (.8814,.9433)	
144	0.5286 (-0.3295,.7811)	114	.7904 (.4092,.8834)	111	.8918 (.8508,.9152)	177	.9097 (.8862,.9440)	
153	0.5471 (-0.2712,.7869)	122	.7958 (.4329,.8849)	113	.8931 (.8530,.9161)	188	.9124 (.8907,.9446)	
163	0.5650 (-0.2145,.7926)	131	.8011 (.4557,.8865)	118	.8953 (.8569,.9176)	201	.9149 (.8949,.9452)	
174	0.5823 (-0.1593,.7981)	141	.8062 (.4777,.8880)	127	.8987 (.8628,.9200)	214	.9174 (.8988,.9459)	
185	0.5989 (-0.1058,.8034)	152	.8112 (.4988,.8895)	136	.9019 (.8685,.9223)	216	.9178 (.8994,.9460)	
197	0.6149 (-0.0539,.8087)	164	.8161 (.5192,.8910)	145	.9051 (.8739,.9247)	229	.9199 (.9027,.9465)	
210	0.6303 (-0.0037,.8137)	176	.8209 (.5389,.8925)	150	.9067 (.8767,.9260)	244	.9222 (.9064,.9471)	
223	0.6451 (0.0450,.8187)	189	.8255 (.5578,.8939)	155	.9081 (.8791,.9271)	260	.9245 (.9099,.9477)	
238	0.6594 (0.0919,.8235)	204	.8300 (.5760,.8954)	166	.9111 (.8841,.9293)	278	.9267 (.9133,.9483)	
253	0.6731 (0.1373,.8282)	219	.8345 (.5935,.8968)	178	.9139 (.8888,.9315)	285	.9276 (.9146,.9486)	
269	0.6863 (0.1810,.8328)	236	.8387 (.6103,.8982)	190	.9167 (.8934,.9336)	296	.9289 (.9166,.9489)	
287	0.6990 (0.2230,.8372)	254	.8429 (.6265,.8996)	191	.9169 (.8938,.9338)	316	.9310 (.9198,.9495)	
305	0.7113 (0.2635,.8416)	273	.8470 (.6421,.9011)	203	.9194 (.8978,.9357)	337	.9330 (.9227,.9504)	
325	0.7230 (0.3023,.8458)	294	.8510 (.6570,.9025)	218	.9220 (.9021,.9377)	360	.9350 (.9254,.9512)	
346	0.7343 (0.3395,.8499)	316	.8549 (.6714,.9040)	233	.9245 (.9061,.9396)	384	.9369 (.9280,.9520)	
368	0.7452 (0.3751,.8539)	340	.8587 (.6852,.9054)	249	.9269 (.9100,.9415)	410	.9388 (.9305,.9528)	

392	0.7556 (0.4092,.8577)	365	.8623 (0.6985,.9068)	266	.9293 (.9136,.9433)	437	.9406 (.9329,.9536)
417	0.7656 (0.4418,.8615)	393	.8659 (0.7112,.9081)	285	.9315 (.9170,.9451)	440	.9408 (.9332,.9537)
444	0.7752 (0.4729,.8652)	423	.8694 (0.7234,.9095)	305	.9337 (.9202,.9468)	466	.9423 (.9352,.9544)
473	0.7845 (0.5025,.8688)	455	.8728 (0.7351,.9108)	326	.9359 (.9233,.9484)	497	.9440 (.9374,.9551)
500	0.7924 (0.5276,.8719)	489	.8761 (0.7464,.9121)	330	.9363 (.9239,.9487)	500	.9442 (.9375,.9552)
504	0.7934 (0.5307,.8723)	500	.8771 (0.7496,.9125)	349	.9380 (.9263,.9500)	531	.9457 (.9394,.9559)
536	0.8019 (0.5575,.8759)	526	.8794 (0.7572,.9134)	373	.9400 (.9292,.9516)	566	.9473 (.9412,.9566)
571	0.8101 (0.5830,.8794)	566	.8825 (0.7675,.9148)	399	.9419 (.9320,.9531)	581	.9479 (.9418,.9569)
608	0.8179 (0.6073,.8828)	609	.8856 (0.7775,.9163)	427	.9438 (.9346,.9546)	604	.9488 (.9427,.9573)
647	0.8255 (0.6302,.8861)	655	.8886 (0.7870,.9178)	454	.9454 (.9369,.9558)	644	.9504 (.9439,.9585)
653	0.8266 (0.6336,.8866)	705	.8915 (0.7961,.9197)	457	.9456 (.9372,.9560)	687	.9518 (.9451,.9596)
689	0.8327 (0.6520,.8893)	758	.8943 (0.8049,.9215)	489	.9473 (.9396,.9573)	733	.9532 (.9463,.9607)
733	0.8397 (0.6726,.8924)	763	.8946 (0.8056,.9216)	500	.9479 (.9404,.9578)	749	.9537 (.9467,.9610)
780	0.8463 (0.6921,.8954)	816	.8971 (0.8133,.9233)	523	.9490 (.9419,.9587)	782	.9546 (.9474,.9619)
831	0.8527 (0.7105,.8983)	877	.8998 (0.8213,.9250)	560	.9507 (.9436,.9600)	835	.9560 (.9485,.9632)
884	0.8589 (0.7279,.9012)	944	.9024 (0.8290,.9268)	599	.9523 (.9449,.9612)	891	.9573 (.9496,.9645)
942	0.8648 (0.7444,.9039)	1000	.9044 (0.8349,.9282)	641	.9538 (.9461,.9624)	950	.9585 (.9507,.9658)
960	0.8666 (0.7494,.9048)	1015	.9050 (0.8364,.9286)	673	.9549 (.9469,.9633)	958	.9587 (.9508,.9659)
1000	0.8702 (0.7593,.9065)	1092	.9075 (0.8435,.9303)	686	.9553 (.9473,.9636)	1000	.9595 (.9514,.9667)
1002	0.8704 (0.7599,.9066)	1139	.9089 (0.8474,.9313)	733	.9568 (.9484,.9647)	1014	.9598 (.9516,.9670)
1067	0.8758 (0.7745,.9092)	1175	.9099 (0.8503,.9320)	785	.9582 (.9494,.9658)	1081	.9610 (.9525,.9681)
1136	0.8810 (0.7883,.9117)	1264	.9123 (0.8568,.9337)	839	.9595 (.9504,.9669)	1154	.9621 (.9531,.9694)
1209	0.8860 (0.8013,.9141)	1360	.9146 (0.8630,.9353)	898	.9608 (.9513,.9679)	1231	.9632 (.9537,.9707)
1288	0.8908 (0.8135,.9165)	1463	.9168 (0.8690,.9368)	909	.9611 (.9515,.9681)	1313	.9643 (.9543,.9719)
1297	0.8914 (0.8150,.9168)	1573	.9190 (0.8747,.9384)	961	.9621 (.9523,.9689)	1401	.9654 (.9549,.9731)
1371	0.8954 (0.8251,.9188)	1693	.9211 (0.8801,.9399)	1000	.9628 (.9528,.9695)	1452	.9659 (.9552,.9737)
1459	0.8998 (0.8359,.9210)	1817	.9231 (0.8852,.9413)	1028	.9633 (.9532,.9699)	1495	.9664 (.9555,.9742)
1553	0.9040 (0.8461,.9232)	1821	.9232 (0.8853,.9413)	1100	.9645 (.9541,.9708)	1595	.9674 (.9560,.9753)
1654	0.9080 (0.8556,.9254)	1959	.9252 (0.8903,.9427)	1177	.9657 (.9550,.9717)	1701	.9684 (.9566,.9763)
1761	0.9119 (0.8645,.9282)	2107	.9272 (0.8951,.9441)	1259	.9668 (.9559,.9726)	1815	.9693 (.9572,.9773)
1874	0.9156 (0.8728,.9309)	2267	.9291 (0.8997,.9455)	1347	.9678 (.9568,.9735)	1840	.9695 (.9573,.9775)
1995	0.9192 (0.8806,.9335)	2438	.9309 (0.9041,.9468)	1441	.9689 (.9576,.9743)	1936	.9702 (.9577,.9783)
2124	0.9226 (0.8880,.9360)	2623	.9328 (0.9083,.9481)	1491	.9694 (.9580,.9747)	2066	.9711 (.9583,.9792)
2261	0.9258 (0.8949,.9387)	2821	.9345 (0.9123,.9494)	1541	.9699 (.9585,.9752)	2204	.9719 (.9588,.9800)
2408	0.9290 (0.9014,.9413)	3035	.9362 (0.9161,.9506)	1649	.9709 (.9593,.9760)	2349	.9728 (.9593,.9808)
2563	0.9320 (0.9075,.9438)	3265	.9379 (0.9196,.9518)	1764	.9718 (.9601,.9768)	2352	.9728 (.9593,.9809)
2729	0.9348 (0.9132,.9463)	3512	.9396 (0.9230,.9530)	1887	.9727 (.9608,.9777)	2509	.9736 (.9599,.9817)
2905	0.9376 (0.9186,.9486)	3607	.9401 (0.9241,.9534)	2019	.9736 (.9616,.9786)	2677	.9744 (.9604,.9824)
2957	0.9384 (0.9201,.9492)	3778	.9412 (0.9262,.9541)	2027	.9737 (.9617,.9786)	2856	.9751 (.9609,.9832)
3092	0.9402 (0.9236,.9508)	4064	.9427 (0.9293,.9552)	2160	.9745 (.9624,.9794)	3047	.9759 (.9614,.9839)
3292	0.9428 (0.9284,.9529)	4372	.9442 (0.9322,.9563)	2311	.9753 (.9631,.9802)	3250	.9766 (.9619,.9846)
3505	0.9452 (0.9328,.9549)	4703	.9457 (0.9351,.9574)	2440	.9759 (.9637,.9809)	3468	.9773 (.9624,.9853)
3731	0.9475 (0.9370,.9569)	5059	.9471 (0.9375,.9584)	2472	.9761 (.9638,.9810)	3699	.9779 (.9629,.9859)
3972	0.9497 (0.9409,.9587)	5443	.9485 (0.9399,.9594)	2645	.9769 (.9645,.9818)	3947	.9786 (.9634,.9865)
4229	0.9519 (0.9445,.9605)	5855	.9499 (0.9421,.9604)	2830	.9776 (.9652,.9825)	4211	.9792 (.9638,.9871)
4502	0.9539 (0.9479,.9622)	6262	.9511 (0.9437,.9613)	3028	.9783 (.9659,.9832)	4492	.9798 (.9643,.9877)
4553	0.9543 (0.9485,.9625)	6298	.9512 (0.9438,.9613)	3239	.9790 (.9666,.9839)	4793	.9804 (.9647,.9882)
4792	0.9559 (0.9500,.9639)	6775	.9525 (0.9450,.9623)	3465	.9797 (.9672,.9845)	5113	.9810 (.9652,.9887)
5102	0.9577 (0.9513,.9654)	7288	.9537 (0.9460,.9632)	3707	.9804 (.9679,.9852)	5455	.9816 (.9656,.9892)
5431	0.9595 (0.9527,.9669)	7840	.9549 (0.9470,.9641)	3966	.9810 (.9685,.9857)	5820	.9821 (.9661,.9897)
5782	0.9612 (0.9539,.9683)	8434	.9561 (0.9477,.9650)	4243	.9816 (.9691,.9863)	6209	.9827 (.9665,.9901)
6156	0.9629 (0.9552,.9697)	9073	.9573 (0.9484,.9661)	4540	.9822 (.9697,.9869)	6625	.9832 (.9670,.9905)
6553	0.9645 (0.9564,.9710)	9688	.9583 (0.9491,.9670)	4857	.9828 (.9703,.9874)	7068	.9837 (.9674,.9909)
6937	0.9658 (0.9575,.9722)	9760	.9584 (0.9491,.9671)	5196	.9834 (.9709,.9880)	7540	.9842 (.9678,.9913)

6976	0.9660 (0.9576,.9723)	10499	.9595 (0.9498,.9681)	5559	.9839 (.9715,.9885)	8044	.9846 (.9681,.9917)
7427	0.9674 (0.9587,.9735)	11294	.9606 (0.9505,.9690)	5947	.9844 (.9720,.9890)	8582	.9851 (.9685,.9921)
7907	0.9688 (0.9598,.9747)	12149	.9616 (0.9512,.9699)	6362	.9849 (.9726,.9894)	9156	.9855 (.9689,.9924)
8417	0.9701 (0.9609,.9759)	13069	.9626 (0.9518,.9708)	6807	.9854 (.9731,.9899)	9769	.9860 (.9692,.9927)
8961	0.9714 (0.9619,.9770)	14059	.9636 (0.9525,.9717)	7282	.9859 (.9736,.9903)	10422	.9864 (.9696,.9931)
9540	0.9726 (0.9629,.9780)	15124	.9646 (0.9531,.9728)	7791	.9864 (.9742,.9907)	11119	.9868 (.9699,.9934)
10145	0.9738 (0.9638,.9791)	15353	.9648 (0.9532,.9730)	8335	.9868 (.9747,.9911)	11862	.9872 (.9703,.9936)
10156	0.9738 (0.9638,.9791)	16269	.9655 (0.9538,.9739)	8917	.9872 (.9752,.9915)	12656	.9875 (.9706,.9939)
10156	0.9738 (0.9638,.9791)	16269	.9655 (0.9538,.9739)	9540	.9876 (.9757,.9919)	13502	.9879 (.9710,.9942)
10156	0.9738 (0.9638,.9791)	16269	.9655 (0.9538,.9739)	10206	.9880 (.9761,.9922)	14405	.9883 (.9713,.9944)
10156	0.9738 (0.9638,.9791)	16269	.9655 (0.9538,.9739)	10919	.9884 (.9766,.9925)	15368	.9886 (.9716,.9947)
223.2	.6451 (.0450,.8187)	26.4	.6482 (-0.2751,.8471)	(,)	(,)	(,)	(,)
1459	.8998 (.8359,.9210)	877	.8998 (0.8213,.9250)	127	.8987 (.8628,.9200)	145	.9013 (.8704,.9420)
3972	.9497 (.9409,.9587)	5855	.9499 (0.9421,.9604)	560	.9507 (.9436,.9600)	644	.9504 (.9439,.9585)

AMOCH

Table 6.6: Controlled VE with sensitivity analysis as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence intervals (10 replicates).

	Anti Spike IgG (BAU/ml)	s	Estimate		Anti RBD IgG (BAU/ml)	s	Estimate		Pseudovirus-nAb cID50	s	Estimate		Pseudovirus-nAb cID80	s	Estimate
20.7	.4248 (-0.4978,.8085)	11.8	.8308 (.3266,.9355)		13.7	.8179 (.6713,.8978)	25.3	.8696 (.7579,.9530)							
22	.4345 (-0.4816,.8103)	13	.8322 (.3369,.9353)		15	.8212 (.6797,.8984)	27	.8713 (.7640,.9527)							
23	.4442 (-0.4649,.8121)	14	.8336 (.3473,.9351)		16	.8244 (.6879,.8990)	29	.8730 (.7700,.9525)							
25	.4540 (-0.4477,.8138)	15	.8351 (.3577,.9349)		17	.8276 (.6960,.8996)	31	.8747 (.7758,.9523)							
27	.4638 (-0.4300,.8156)	16	.8365 (.3683,.9346)		18	.8308 (.7040,.9002)	33	.8764 (.7816,.9521)							
28	.4735 (-0.4120,.8174)	17	.8379 (.3789,.9344)		19	.8339 (.7118,.9009)	35	.8781 (.7872,.9519)							
30	.4833 (-0.3935,.8192)	18	.8393 (.3896,.9342)		20	.8370 (.7195,.9015)	37	.8798 (.7927,.9517)							
32	.4931 (-0.3745,.8210)	20	.8407 (.4003,.9340)		22	.8401 (.7270,.9021)	40	.8814 (.7981,.9515)							
34	.5029 (-0.3552,.8228)	21	.8422 (.4111,.9338)		23	.8431 (.7344,.9028)	42	.8831 (.8035,.9513)							
36	.5126 (-0.3355,.8246)	23	.8436 (.4218,.9336)		25	.8461 (.7416,.9034)	45	.8848 (.8087,.9511)							
39	.5223 (-0.3154,.8264)	25	.8450 (.4326,.9334)		27	.8491 (.7487,.9041)	48	.8864 (.8139,.9510)							
41	.5319 (-0.2950,.8282)	26	.8464 (.4435,.9333)		29	.8520 (.7557,.9048)	52	.8881 (.8189,.9508)							
44	.5416 (-0.2742,.8301)	28	.8479 (.4543,.9331)		31	.8549 (.7625,.9055)	55	.8898 (.8239,.9507)							
47	.5511 (-0.2530,.8319)	31	.8493 (.4650,.9329)		33	.8577 (.7691,.9062)	59	.8914 (.8287,.9505)							
50	.5606 (-0.2315,.8337)	33	.8507 (.4758,.9327)		35	.8606 (.7757,.9069)	63	.8931 (.8335,.9504)							
53	.5700 (-0.2096,.8355)	35	.8522 (.4866,.9325)		38	.8633 (.7821,.9076)	67	.8947 (.8382,.9503)							
56	.5794 (-0.1875,.8373)	38	.8536 (.4972,.9324)		40	.8661 (.7883,.9083)	71	.8963 (.8427,.9501)							
60	.5886 (-0.1650,.8391)	41	.8550 (.5079,.9322)		43	.8688 (.7945,.9090)	76	.8980 (.8472,.9500)							
64	.5978 (-0.1422,.8409)	44	.8564 (.5185,.9320)		46	.8715 (.8005,.9097)	81	.8996 (.8516,.9499)							
68	.6069 (-0.1191,.8428)	47	.8579 (.5290,.9319)		49	.8742 (.8063,.9105)	87	.9012 (.8559,.9498)							
72	.6159 (-0.0957,.8446)	51	.8593 (.5394,.9317)		53	.8768 (.8121,.9112)	92	.9029 (.8602,.9498)							
77	.6248 (-0.0720,.8464)	55	.8607 (.5498,.9316)		56	.8794 (.8177,.9120)	99	.9045 (.8643,.9497)							
82	.6335 (-0.0481,.8482)	59	.8622 (.5601,.9314)		60	.8820 (.8232,.9127)	105	.9061 (.8683,.9496)							
87	.6422 (-0.0240,.8499)	63	.8636 (.5703,.9313)		65	.8845 (.8285,.9135)	112	.9077 (.8723,.9496)							
93	.6508 (0.0003,.8517)	68	.8650 (.5803,.9312)		69	.8870 (.8337,.9143)	120	.9093 (.8762,.9496)							
99	.6592 (0.0249,.8535)	73	.8664 (.5903,.9311)		74	.8895 (.8389,.9153)	128	.9110 (.8800,.9496)							
105	.6675 (0.0496,.8553)	79	.8679 (.6002,.9309)		79	.8919 (.8439,.9168)	136	.9126 (.8837,.9496)							
112	.6757 (0.0744,.8571)	85	.8693 (.6099,.9308)		85	.8943 (.8487,.9184)	145	.9142 (.8874,.9496)							
119	.6838 (0.0994,.8588)	91	.8707 (.6195,.9307)		90	.8967 (.8535,.9199)	155	.9158 (.8909,.9496)							
127	.6918 (0.1244,.8606)	98	.8721 (.6290,.9306)		97	.8991 (.8582,.9214)	165	.9174 (.8944,.9496)							
135	.6996 (0.1495,.8624)	106	.8736 (.6384,.9305)		104	.9014 (.8627,.9230)	166	.9174 (.8946,.9496)							
144	.7073 (0.1746,.8641)	114	.8750 (.6476,.9304)		111	.9037 (.8671,.9245)	177	.9190 (.8978,.9497)							
153	.7149 (0.1997,.8658)	122	.8764 (.6567,.9303)		113	.9045 (.8687,.9250)	188	.9206 (.9009,.9498)							
163	.7223 (0.2247,.8676)	131	.8778 (.6656,.9303)		118	.9059 (.8715,.9260)	201	.9221 (.9038,.9499)							
174	.7296 (0.2496,.8693)	141	.8792 (.6744,.9302)		127	.9082 (.8757,.9275)	214	.9237 (.9065,.9500)							
185	.7368 (0.2744,.8710)	152	.8806 (.6831,.9301)		136	.9104 (.8798,.9290)	216	.9240 (.9069,.9500)							
197	.7439 (0.2991,.8727)	164	.8821 (.6916,.9301)		145	.9125 (.8838,.9307)	229	.9253 (.9093,.9501)							
210	.7508 (0.3235,.8745)	176	.8835 (.7000,.9301)		150	.9137 (.8859,.9315)	244	.9269 (.9120,.9503)							
223	.7576 (0.3476,.8762)	189	.8849 (.7082,.9300)		155	.9147 (.8877,.9323)	260	.9285 (.9146,.9505)							
238	.7643 (0.3715,.8778)	204	.8863 (.7163,.9300)		166	.9168 (.8916,.9339)	278	.9301 (.9173,.9507)							
253	.7708 (0.3950,.8795)	219	.8877 (.7242,.9300)		178	.9189 (.8953,.9355)	285	.9307 (.9183,.9507)							
269	.7772 (0.4182,.8812)	236	.8891 (.7320,.9300)		190	.9210 (.8989,.9371)	296	.9316 (.9198,.9509)							
287	.7835 (0.4409,.8829)	254	.8905 (.7396,.9300)		191	.9211 (.8992,.9372)	316	.9332 (.9224,.9512)							
305	.7896 (0.4633,.8845)	273	.8919 (.7471,.9301)		203	.9230 (.9025,.9386)	337	.9348 (.9248,.9517)							
325	.7956 (0.4852,.8862)	294	.8933 (.7544,.9302)		218	.9251 (.9059,.9402)	360	.9363 (.9270,.9522)							
346	.8015 (0.5065,.8878)	316	.8947 (.7616,.9303)		233	.9270 (.9093,.9417)	384	.9379 (.9291,.9528)							
368	.8073 (0.5274,.8895)	340	.8961 (.7686,.9304)		249	.9290 (.9126,.9432)	410	.9395 (.9313,.9534)							
392	.8129 (0.5478,.8911)	365	.8975 (.7755,.9306)		266	.9310 (.9156,.9447)	437	.9410 (.9334,.9540)							
417	.8184 (0.5676,.8927)	393	.8989 (.7822,.9307)		285	.9329 (.9186,.9461)	440	.9412 (.9336,.9541)							

444	.8238 (.5868,.8943)	423	.9003 (.7888,.9309)	305	.9348 (.9214,.9476)	466	.9426 (.9355,.9546)
473	.8291 (.6055,.8960)	455	.9017 (.7952,.9310)	326	.9366 (.9242,.9490)	497	.9442 (.9375,.9552)
500	.8337 (.6216,.8974)	489	.9031 (.8015,.9312)	330	.9370 (.9247,.9493)	500	.9443 (.9377,.9553)
504	.8343 (.6236,.8976)	500	.9035 (.8034,.9313)	349	.9385 (.9269,.9505)	531	.9457 (.9395,.9559)
536	.8393 (.6411,.8993)	526	.9045 (.8077,.9314)	373	.9403 (.9296,.9519)	566	.9473 (.9412,.9566)
571	.8442 (.6580,.9011)	566	.9058 (.8137,.9317)	399	.9421 (.9322,.9533)	581	.9479 (.9418,.9569)
608	.8490 (.6744,.9028)	609	.9072 (.8196,.9321)	427	.9439 (.9347,.9546)	604	.9488 (.9427,.9573)
647	.8538 (.6901,.9045)	655	.9086 (.8253,.9326)	454	.9454 (.9369,.9558)	644	.9503 (.9438,.9584)
653	.8545 (.6925,.9048)	705	.9100 (.8309,.9334)	457	.9456 (.9372,.9560)	687	.9517 (.9450,.9595)
689	.8584 (.7053,.9063)	758	.9114 (.8364,.9341)	489	.9473 (.9396,.9573)	733	.9530 (.9460,.9605)
733	.8628 (.7199,.9079)	763	.9115 (.8368,.9342)	500	.9479 (.9404,.9578)	749	.9534 (.9463,.9608)
780	.8672 (.7339,.9096)	816	.9128 (.8417,.9349)	523	.9490 (.9419,.9587)	782	.9542 (.9470,.9616)
831	.8715 (.7474,.9113)	877	.9142 (.8469,.9358)	560	.9506 (.9436,.9599)	835	.9554 (.9479,.9628)
884	.8757 (.7603,.9129)	944	.9155 (.8520,.9367)	599	.9522 (.9447,.9611)	891	.9565 (.9488,.9639)
942	.8797 (.7727,.9146)	1000	.9166 (.8560,.9374)	641	.9536 (.9459,.9623)	950	.9576 (.9496,.9650)
960	.8810 (.7765,.9151)	1015	.9169 (.8570,.9376)	673	.9547 (.9466,.9630)	958	.9577 (.9497,.9651)
1000	.8836 (.7841,.9161)	1092	.9183 (.8618,.9385)	686	.9550 (.9469,.9633)	1000	.9584 (.9502,.9658)
1002	.8837 (.7845,.9162)	1139	.9191 (.8645,.9390)	733	.9564 (.9479,.9644)	1014	.9586 (.9503,.9660)
1067	.8876 (.7959,.9178)	1175	.9197 (.8665,.9394)	785	.9576 (.9487,.9654)	1081	.9596 (.9508,.9670)
1136	.8914 (.8067,.9194)	1264	.9210 (.8711,.9403)	839	.9588 (.9495,.9663)	1154	.9605 (.9511,.9682)
1209	.8951 (.8171,.9210)	1360	.9224 (.8756,.9412)	898	.9600 (.9503,.9672)	1231	.9614 (.9514,.9693)
1288	.8987 (.8270,.9225)	1463	.9238 (.8800,.9422)	909	.9602 (.9504,.9674)	1313	.9623 (.9517,.9703)
1297	.8991 (.8282,.9227)	1573	.9252 (.8842,.9431)	961	.9611 (.9510,.9681)	1401	.9631 (.9519,.9713)
1371	.9022 (.8364,.9241)	1693	.9265 (.8884,.9440)	1000	.9617 (.9515,.9686)	1452	.9635 (.9520,.9719)
1459	.9056 (.8454,.9256)	1817	.9279 (.8923,.9449)	1028	.9622 (.9517,.9689)	1495	.9639 (.9521,.9723)
1553	.9089 (.8540,.9272)	1821	.9279 (.8924,.9449)	1100	.9632 (.9524,.9697)	1595	.9646 (.9523,.9732)
1654	.9122 (.8621,.9288)	1959	.9293 (.8963,.9459)	1177	.9642 (.9531,.9705)	1701	.9654 (.9525,.9741)
1761	.9154 (.8698,.9310)	2107	.9307 (.9002,.9468)	1259	.9651 (.9537,.9712)	1815	.9661 (.9527,.9749)
1874	.9184 (.8771,.9332)	2267	.9320 (.9039,.9478)	1347	.9660 (.9543,.9719)	1840	.9662 (.9527,.9751)
1995	.9214 (.8840,.9354)	2438	.9334 (.9075,.9487)	1441	.9669 (.9549,.9726)	1936	.9667 (.9528,.9757)
2124	.9244 (.8906,.9375)	2623	.9348 (.9111,.9497)	1491	.9673 (.9552,.9730)	2066	.9674 (.9529,.9765)
2261	.9272 (.8969,.9398)	2821	.9361 (.9145,.9506)	1541	.9677 (.9555,.9734)	2204	.9680 (.9530,.9772)
2408	.9300 (.9029,.9422)	3035	.9375 (.9178,.9516)	1649	.9685 (.9560,.9741)	2349	.9686 (.9531,.9779)
2563	.9327 (.9085,.9445)	3265	.9389 (.9208,.9525)	1764	.9693 (.9565,.9748)	2352	.9686 (.9531,.9779)
2729	.9353 (.9139,.9467)	3512	.9403 (.9239,.9535)	1887	.9701 (.9570,.9755)	2509	.9692 (.9532,.9786)
2905	.9379 (.9190,.9488)	3607	.9408 (.9249,.9539)	2019	.9708 (.9575,.9763)	2677	.9698 (.9533,.9793)
2957	.9386 (.9204,.9494)	3778	.9416 (.9268,.9545)	2027	.9708 (.9575,.9763)	2856	.9703 (.9533,.9799)
3092	.9404 (.9239,.9509)	4064	.9430 (.9296,.9554)	2160	.9715 (.9580,.9770)	3047	.9708 (.9534,.9806)
3292	.9428 (.9285,.9530)	4372	.9444 (.9324,.9564)	2311	.9722 (.9584,.9777)	3250	.9713 (.9534,.9812)
3505	.9452 (.9328,.9550)	4703	.9458 (.9352,.9574)	2440	.9727 (.9588,.9783)	3468	.9718 (.9534,.9817)
3731	.9475 (.9370,.9569)	5059	.9471 (.9376,.9584)	2472	.9728 (.9589,.9784)	3699	.9723 (.9534,.9823)
3972	.9497 (.9408,.9587)	5443	.9485 (.9399,.9594)	2645	.9735 (.9593,.9791)	3947	.9728 (.9534,.9829)
4229	.9518 (.9444,.9605)	5855	.9498 (.9421,.9604)	2830	.9741 (.9597,.9798)	4211	.9732 (.9534,.9834)
4502	.9538 (.9477,.9621)	6262	.9510 (.9437,.9612)	3028	.9747 (.9601,.9804)	4492	.9737 (.9533,.9839)
4553	.9541 (.9483,.9624)	6298	.9511 (.9437,.9613)	3239	.9752 (.9605,.9810)	4793	.9741 (.9533,.9844)
4792	.9556 (.9497,.9637)	6775	.9523 (.9448,.9622)	3465	.9758 (.9609,.9815)	5113	.9745 (.9533,.9848)
5102	.9574 (.9510,.9651)	7288	.9535 (.9458,.9630)	3707	.9763 (.9612,.9821)	5455	.9749 (.9532,.9853)
5431	.9591 (.9521,.9665)	7840	.9546 (.9466,.9638)	3966	.9769 (.9616,.9826)	5820	.9753 (.9531,.9857)
5782	.9607 (.9533,.9679)	8434	.9556 (.9471,.9646)	4243	.9774 (.9619,.9831)	6209	.9757 (.9531,.9861)
6156	.9622 (.9543,.9691)	9073	.9566 (.9476,.9656)	4540	.9779 (.9623,.9836)	6625	.9760 (.9530,.9865)
6553	.9636 (.9554,.9703)	9688	.9575 (.9480,.9663)	4857	.9783 (.9626,.9841)	7068	.9764 (.9529,.9869)
6937	.9649 (.9563,.9714)	9760	.9576 (.9481,.9664)	5196	.9788 (.9629,.9846)	7540	.9768 (.9528,.9873)
6976	.9650 (.9564,.9715)	10499	.9585 (.9485,.9673)	5559	.9792 (.9632,.9851)	8044	.9771 (.9526,.9877)
7427	.9663 (.9573,.9726)	11294	.9594 (.9490,.9681)	5947	.9797 (.9635,.9856)	8582	.9774 (.9524,.9880)

7907	.9675	(.9582,.9737)	12149	.9602	(.9494,.9688)	6362	.9801	(.9638,.9860)	9156	.9778	(.9522,.9884)
8417	.9687	(.9590,.9748)	13069	.9610	(.9497,.9695)	6807	.9805	(.9641,.9865)	9769	.9781	(.9520,.9887)
8961	.9698	(.9598,.9757)	14059	.9618	(.9501,.9703)	7282	.9809	(.9644,.9869)	10422	.9784	(.9518,.9890)
9540	.9709	(.9606,.9767)	15124	.9625	(.9504,.9712)	7791	.9813	(.9646,.9873)	11119	.9787	(.9516,.9893)
10145	.9719	(.9613,.9776)	15353	.9627	(.9505,.9714)	8335	.9817	(.9649,.9877)	11862	.9790	(.9514,.9896)
10156	.9720	(.9613,.9776)	16269	.9633	(.9507,.9722)	8917	.9821	(.9652,.9881)	12656	.9793	(.9511,.9899)
10156	.9720	(.9613,.9776)	16269	.9633	(.9507,.9722)	9540	.9824	(.9654,.9884)	13502	.9796	(.9509,.9902)
10156	.9720	(.9613,.9776)	16269	.9633	(.9507,.9722)	10206	.9828	(.9657,.9888)	14405	.9799	(.9507,.9904)
10156	.9720	(.9613,.9776)	16269	.9633	(.9507,.9722)	10919	.9831	(.9659,.9891)	15368	.9801	(.9504,.9907)
223.2	.6451	(.0450,.8187)	26.4	.6482	(-0.2751,.8471)			(,)			(,)
1459	.8998	(.8359,.9210)	877	.8998	(.8213,.9250)	127	.8987	(.8628,.9200)	145	.9013	(.8704,.9420)
3972	.9497	(.9409,.9587)	5855	.9499	(0.9421,.9604)	560	.9507	(.9436,.9600)	644	.9504	(.9439,.9585)

MOCY

6.3 Misc

Average follow-up of vaccine recipients (in the D57 correlates analyses population) starting at 7 days post Day 57 visit (not counting the 7 days) is 166 days.

Number of breakthrough vaccine cases (in the Day 57 correlates analyses population) with Day 57 ID80 > 660 IU: 16 .




Figure 6.12: Distribution of the number of days between visits in the per-protocol immunogenicity subcohort, vaccine arm, baseline negative. The median (IQR) number of days between Day 1 and Day 29 was 29 (27-31) . The median (IQR) number of days between Day 29 and Day 57 was 28 (25-31) .

Table 6.7: Deciles of Day 57 cID50 titer for the immunogenicity subcohort in the vaccine arm.

	min	10%	20%	30%	40%	50%	60%	70%	80%	90%	max
Baseline negative											
All	14	93	151	217	292	423	577	823	1244	2163	26376
Age \geq 65, URM	31	207	331	451	583	780	963	1350	1915	2500	11184
Age < 65, At risk, URM	48	103	146	175	269	435	571	755	1019	1695	5068
Age < 65, Not at risk, URM	52	127	164	238	307	394	508	788	1291	2163	6502
Age \geq 65, White non-Hisp	14	186	297	460	685	935	1147	1745	2428	4130	26376
Age < 65, At risk, White non-Hisp	27	82	139	182	239	350	485	690	1029	1769	4887
Age < 65, Not at risk, White non-Hisp	14	68	114	160	222	288	427	578	902	1525	10510
Baseline positive											
All	26	222	499	719	886	1281	1795	2322	3868	5389	58805
Age \geq 65, URM	173	483	839	1247	1974	2599	4004	5238	6134	11957	35230
Age < 65, At risk, URM	83	197	222	631	841	886	1180	1518	5096	5389	58805
Age < 65, Not at risk, URM	54	285	478	549	730	755	1233	1726	2273	3979	4842
Age \geq 65, White non-Hisp	261	546	843	1172	1486	2069	2760	3925	5777	15777	27448
Age < 65, At risk, White non-Hisp	26	243	639	707	904	1086	1445	1835	2392	3868	8543
Age < 65, Not at risk, White non-Hisp	31	170	399	592	816	1676	2006	2322	3757	5082	22574

Table 6.8: Summary statistics for the number of days from dose 1 to Day 57 visit. (a) The whole immunogenicity subcohort, (b) non-cases in the immunogenicity subcohort, (c) intercurrent cases, (d) primary cases, i.e. cases from the Day 57 correlates analysis population.

	min	1st quartile	median	3d quartile	max
(a)	51	54	57	60	63
(b)	51	55	58	61	63
(c)	54	56	58	61	62
(d)	51	55	58	60	63

MOCK

Chapter 7

Univariate CoR: Nonparametric Threshold Modeling ($>= s$)

An extension of the unadjusted nonparametric threshold-searching approach developed in Donovan, Hudgens, and Gilbert (2019), the covariate-adjusted TMLE-based approach developed by van der Laan, Zhang, Gilbert (submitted) is used to estimate the so-called threshold-response function $E_X[E[Y | S \geq s, X, A = 1] | A = 1]$ for a range of thresholds s . Here, X is a set of baseline characteristics, $A = 1$ represents the vaccine group, S is the biomarker/immune-response/correlate of interest, and Y is the indicator of COVID disease before some time point t_f . This parameter can be viewed as a causal/covariate-adjusted version of the parameter $P(Y = 1 | S \geq s, A = 1)$. Intuitively, the threshold-response at a given threshold is the expected probability of obtaining COVID disease if one experiences a marker/immune-response value above that threshold. The threshold-response function is estimated for each of the four Day 57 antibody markers, in each case adjusting for the baseline covariates: baseline risk score, high risk indicator, and underrepresented minority status. A restrictive but flexible specification of the Highly Adaptive Lasso estimator is used for the covariate adjustment. A number of plots and tables are reported:

1. A plot and table with risk estimates and point-wise 95% confidence intervals
2. A plot and table with risk estimates and simultaneous 95% confidence bands
3. Monotone-corrected versions of 1 and 2.

A reverse cumulative distribution function curve estimated by the IPW NPMLE of the marker values is superimposed on the threshold-response plots and a dashed red line is added to mark the threshold value after which no more events are observed.

The blue dots on the plots represent the risk predictions at marker values where there was an observed COVID-19 case.

7.1 Plots and Tables with estimates and pointwise confidence interval for Day 57

MOCK

7.2 Plots and Tables with estimates and pointwise confidence intervals for Day 29

MOCK

7.3 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)

MOCK

7.4 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)

MOCK

7.5 Plots and Tables with estimates and simultaneous confidence bands for Day 57

MOCK

7.6 Plots and Tables with estimates and simultaneous confidence bands for Day 29

MOCK

7.7 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)

MOCK

7.8 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)

MOCK

MOCK

Chapter 8

Univariate CoR: Nonparametric Threshold Modeling ($\leq s$)

The same methodology as the previous section is apply to estimate the “below” threshold-response function $E_{WE}[Y = 1|A = 1, X, S \leq s]$.

8.1 Plots and Tables with estimates and pointwise confidence interval for Day 57

8.2 Plots and Tables with estimates and pointwise confidence intervals for Day 29

MOCK

8.3 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)

MOCK

8.4 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)

MOCK

8.5 Plots and Tables with estimates and simultaneous confidence bands for Day 57

MOCK

8.6 Plots and Tables with estimates and simultaneous confidence bands for Day 29

MOCK

8.7 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)

MOCK

8.8 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)

MOCK

Chapter 9

Day D29 Univariate CoR: Nonlinear modeling

To explore nonlinear association and threshold modeling, we fit smoothing spline models with degrees of freedom selected by cross-validation using the mgcv R package.




Figure 9.1: Marginalized risk as functions of Day 29 markers ($=s$) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: baseline risk score, meeting the protocol randomization criterion for being at heightened risk of COVID (yes or no), community of color or not. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.

Chapter 10

Day D57 Univariate CoR: Nonlinear modeling

To explore nonlinear association and threshold modeling, we fit smoothing spline models with degrees of freedom selected by cross-validation using the mgcv R package.




Figure 10.1: Marginalized risk as functions of Day 57 markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. Baseline covariates adjusted for: baseline risk score, meeting the protocol randomization criterion for being at heightened risk of COVID (yes or no), community of color or not. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.

Chapter 11

Appendix

- This report was built from the [CoVPN/correlates_reporting](#) repository with commit hash d09dd2c09b131bee74fedfb5b9159f748ce3b3b0. A diff of the changes introduced by that commit may be viewed at https://github.com/CoVPN/correlates_reporting/commit/d09dd2c09b131bee74fedfb5b9159f748ce3b3b0
- The sha256 hash sum of the raw input file, “COVID_VEtiral_practicedata_primarystage1.csv”: 83d0f55d1745ffd42be124d8f9ec9a9903abcc13cd22f95e537542a08b41300a
- The sha256 hash sum of the processed file, “moderna_mock_data_processed.csv”: d806a7fb38690eff7ecb69f0bd6f74afc5